[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 410
1. Oshiro S, Tsugu H, Komatsu F, Ohnishi H, Ueno Y, Sakamoto S, Fukushima T, Soma G: Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. Anticancer Res; 2006 Nov-Dec;26(6A):4027-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma.
  • BACKGROUND: This study assessed safety and efficacy for intratumoral administration of tumor necrosis factor-a (TNF-SAM2) into the post-operative tumor cavity through an Ommaya reservoir for patients with malignant glioma.
  • MATERIALS AND METHODS: Seven patients with malignant glioma, comprising 3 cases with glioblastoma multiforme (GBM), 3 cases with anaplastic astrocytoma (AA) and 1 case with malignant ependymoma (ME) were included in the study.
  • TNF-SAM2 was administrated into the post-operative tumor cavity through a reservoir at a concentration of 1x10(4) U/body when recurrence was detected, or as initial induction therapy concomitant with radiotherapy.
  • RESULTS: Partial response to this regional immunotherapy was seen in 4 out of 7 patients, and 1 patient with GBM has remained clinically stable for >184 weeks without tumor progression.
  • With AA, 2 cases appeared to display slowed advance and longer times to tumor recurrence or regrowth.
  • No serious adverse effects, such as brain edema, hemorrhage or seizure were observed, nor systemic toxicities.
  • [MeSH-major] Glioma / therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Injections, Intralesional. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195453.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / TNF-SAM2; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


2. Balik V, Mirossay P, Bohus P, Sulla I, Mirossay L, Sarissky M: Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. Cell Mol Neurobiol; 2009 Sep;29(6-7):845-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) represents an extremely chemoresistant tumour type.
  • The expression of selected neural and non-neural differentiation markers including A2B5, CD34, CD45, CD56, CD117, CD133, EGFR, GFAP, Her-2/neu, LIFR, nestin, NGFR, Pgp and vimentin was analysed by flow cytometry in eleven GBM (WHO gr.IV) patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Glioblastoma / drug therapy. Glioblastoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor. Cell Differentiation. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Neurons / pathology. Predictive Value of Tests. Tumor Cells, Cultured


3. Perry SL, Bohlin C, Reardon DA, Desjardins A, Friedman AH, Friedman HS, Vredenburgh JJ: Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol; 2009 Oct;95(1):129-134
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
  • The purpose of this study was to determine the safety of tinzaparin for deep vein thrombosis prophylaxis in newly diagnosed grade III-IV malignant glioma patients.
  • Forty patients were enrolled into the study, 35 with glioblastoma multiforme and 5 with anaplastic astrocytoma.
  • Possible attributable toxicity was limited to two patients who developed CNS hemorrhages (one grade 1 and one grade 2) and one patient with an increase in liver enzymes (grade 3).
  • There were no patients with a grade 4 or 5 CNS hemorrhages or systemic hemorrhages >or=grade 2.
  • Tinzaparin at a fixed prophylactic dose is safe and may decrease the incidence of thromboembolic complications in brain tumor patients.
  • [MeSH-major] Brain Neoplasms / complications. Fibrinolytic Agents / therapeutic use. Glioma / complications. Heparin, Low-Molecular-Weight / therapeutic use. Venous Thromboembolism / etiology. Venous Thromboembolism / prevention & control
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pulmonary Embolism / etiology. Pulmonary Embolism / prevention & control. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Thromb Haemost. 2007 May;5(5):955-62 [17461929.001]
  • [Cites] Surg Neurol. 2008 Aug;70(2):117-21; discussion 121 [18262633.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):355-60 [18436627.001]
  • [Cites] J Thromb Haemost. 2010 Sep;8(9):1959-65 [20598077.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Oncologist. 1999;4(6):443-9 [10631688.001]
  • [Cites] Arch Intern Med. 2000 Aug 14-28;160(15):2327-32 [10927730.001]
  • [Cites] Chest. 2001 Jan;119(1 Suppl):132S-175S [11157647.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):163-9 [11285554.001]
  • [Cites] Arch Intern Med. 2001 May 28;161(10):1268-79 [11371254.001]
  • [Cites] J Neurosurg Sci. 2001 Dec;45(4):195-201; discussion 201 [11912469.001]
  • [Cites] J Neurooncol. 2002 Aug;59(1):39-47 [12222837.001]
  • [Cites] J Neurol. 2002 Oct;249(10):1409-12 [12382158.001]
  • [Cites] Chest. 2002 Dec;122(6):1933-7 [12475829.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):109-11 [12853582.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):146-53 [12853587.001]
  • [Cites] South Med J. 2004 Feb;97(2):213-4 [14982286.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1266-71 [15304029.001]
  • [Cites] Ann Neurol. 1983 Mar;13(3):334-6 [6303201.001]
  • [Cites] JAMA. 1988 Sep 2;260(9):1255-8 [3404638.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):152-6 [1352573.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):329-32 [8170176.001]
  • [Cites] Neurology. 1993 Jun;43(6):1111-4 [8170553.001]
  • [Cites] Thromb Haemost. 1996 Feb;75(2):233-8 [8815566.001]
  • [Cites] N Engl J Med. 1996 Sep 5;335(10):701-7 [8703169.001]
  • [Cites] N Engl J Med. 1997 Sep 4;337(10):688-98 [9278467.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1099-103 [9278651.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):80-5 [9654538.001]
  • [Cites] J Formos Med Assoc. 1999 May;98(5):365-7 [10420706.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2123-9 [15699480.001]
  • (PMID = 19415455.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K23 HL084233-02; United States / NHLBI NIH HHS / HL / K23 HL084233-03; United States / NHLBI NIH HHS / HL / K23 HL084233; United States / NHLBI NIH HHS / HL / K23 HL084233-01A1; United States / NHLBI NIH HHS / HL / K23-HL084233-02
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Heparin, Low-Molecular-Weight; 7UQ7X4Y489 / tinzaparin
  • [Other-IDs] NLM/ NIHMS180651; NLM/ PMC2837514
  •  go-up   go-down


Advertisement
4. Usery JB, Michael LM 2nd, Sills AK, Finch CK: A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol; 2010 Sep;99(2):251-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures.
  • To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection.
  • Brain tumor patients undergoing neurosurgery with >or=1 seizure within the preceding month prior to surgery were enrolled to receive intravenous levetiracetam for a minimum of 48 h, transitioned to oral levetiracetam at the same dose, and followed for 1-month after discharge.
  • The most common type of tumor was glioblastoma multiforme.
  • [MeSH-major] Anticonvulsants / administration & dosage. Brain Neoplasms / complications. Glioma / complications. Piracetam / analogs & derivatives. Seizures / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dose-Response Relationship, Drug. Drug Interactions. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Seizures.
  • Hazardous Substances Data Bank. PIRACETAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2010 Dec;100(3):491-2 [20461444.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):227-35 [18240916.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] J Neurooncol. 2009 Jul;93(3):349-54 [19169651.001]
  • [Cites] Stroke. 2005 Mar;36(3):583-7 [15662039.001]
  • [Cites] Epilepsia. 1999 Mar;40(3):341-4 [10080516.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):152-8 [11465395.001]
  • [Cites] Neurology. 1990 Jan;40(1):158-60 [2296364.001]
  • [Cites] Arch Neurol. 1995 Jul;52(7):717-24 [7619029.001]
  • [Cites] J Neurooncol. 2006 May;78(1):99-102 [16541329.001]
  • [Cites] Neurology. 1996 Apr;46(4):985-91 [8780077.001]
  • [Cites] Rev Neurol (Paris). 1992;148(6-7):477-87 [1448668.001]
  • [Cites] J Neurooncol. 2007 Sep;84(3):293-6 [17431542.001]
  • [Cites] Curr Opin Neurol. 1996 Dec;9(6):424-8 [9007399.001]
  • [Cites] Surg Neurol. 1981 Dec;16(6):399-401 [7330758.001]
  • [Cites] Aging (Milano). 1998 Aug;10(4):332-8 [9825025.001]
  • [Cites] Epilepsy Behav. 2008 Apr;12(3):477-80 [18291724.001]
  • [Cites] Neurology. 2008 Aug 26;71(9):665-9 [18725591.001]
  • [Cites] Can J Neurol Sci. 2003 May;30(2):106-12 [12774949.001]
  • (PMID = 20146087.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 230447L0GL / etiracetam; ZH516LNZ10 / Piracetam
  •  go-up   go-down


5. Oshiro S, Tsugu H, Komatsu F, Abe H, Onishi H, Ohmura T, Iwaasa M, Sakamoto S, Fukushima T: Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer Res; 2007 Nov-Dec;27(6A):3757-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Eight patients with histologically verified gliomas, comprising 2 cases with glioblastoma multiforme (GBM, grade 4), 5 cases with anaplastic oligodendroglioma (AO, grade 3; high-grade glioma), and 1 case with fibrillary astrocytoma (FA, grade 2; low-grade glioma) were evaluated using the 1H-MRS protocol following conventional MR imaging, diffusion-weighted imaging (DWI), and perfusion-weighted imaging (PWI) preoperatively.
  • RESULTS: High-grade gliomas tended to demonstrate signal hyperintensity by DWI and higher relative cerebral blood volume (rCBV) by PWI.
  • Increased ratios of choline (Cho) to N-acetylaspartate (NAA) (Cho/NAA) and Cho to creatine (Cr) (Cho/Cr) correlated highly with tumor malignancy.
  • The presence of lactate and lipid was predominately detected in patients with high-grade glioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Diffusion Magnetic Resonance Imaging. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970039.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


6. Arslan M, Karadeniz AN, Aksu G, Güveli M, Fayda M, Doğan AK, Akyüz F: Postoperative hypofractionated radiotherapy in glioblastoma multiforme. J BUON; 2006 Jan-Mar;11(1):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative hypofractionated radiotherapy in glioblastoma multiforme.
  • PURPOSE: To evaluate the safety and efficacy of hypofractionated radiotherapy (HRT) in glioblastoma multiforme (GM) patients in terms of overall and progression-free survival.
  • PATIENTS AND METHODS: Adult patients with GM were prospectively treated with HRT after total, subtotal or partial tumor excision.
  • HRT was applied 3 days a week with a tumor dose of 3.33 Gy per fraction.
  • The tumor was multifocal in one (5%) case.
  • The types of operations used were total tumor excision 10(50%) cases, subtotal excision 5 (25%) cases and partial excision 5 (25%) cases.
  • Acute toxicity was minimal and only one HRT patient had late toxicity (brain necrosis).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Pilot Projects. Postoperative Period. Prognosis. Prospective Studies. Radiotherapy Planning, Computer-Assisted. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318950.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, Qiu X, Jiang T, Zhang W, Song SW: Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol; 2009 Oct;11(5):468-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
  • We found that preoperative plasma IGFBP-2 levels were significantly higher in high-grade glioma patients (n = 43 for grade III glioma; n = 72 for glioblastoma multiforme [GBM]) than in healthy controls (n = 55; p < 0.001) and low-grade (grade II) glioma patients (n = 81; p < 0.001).
  • No significant differences in preoperative plasma IGFBP-2 levels were observed between grade III glioma and GBM patients or between grade II glioma patients and healthy controls.
  • We conclude that preoperative plasma IGFBP-2 levels are significantly higher in high-grade glioma patients than in low-grade glioma patients and healthy subjects, and are significantly correlated with recurrence and DFS in patients with GBM.
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / blood. Glioma / blood. Insulin-Like Growth Factor Binding Protein 2 / blood
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / blood. Neurosurgical Procedures. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1758-64 [10528027.001]
  • [Cites] Growth Horm IGF Res. 2006 Aug;16(4):224-39 [16893667.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5698-704 [17020973.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5563-8 [17372210.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 May;66(5):405-17 [17483698.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):233-9 [17285230.001]
  • [Cites] J Biol Chem. 2007 Jun 22;282(25):18634-44 [17475624.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41 [17606927.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Aug;5(7):737-42 [17692178.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):813-21 [17765190.001]
  • [Cites] Brain. 2007 Dec;130(Pt 12):3336-41 [17998256.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(2):112-20 [17998918.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Endocrinology. 2001 Apr;142(4):1652-8 [11250947.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):95-107 [11770905.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):833-41 [11821468.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4315-21 [12907597.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13970-5 [14617774.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Vitam Horm. 1993;47:1-114 [7680510.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):229-33 [7686915.001]
  • [Cites] Int J Cancer. 1994 May 15;57(4):491-7 [7514152.001]
  • [Cites] Eur J Pediatr. 1996 Feb;155(2):81-6 [8775218.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Mar;46(3):333-42 [9156044.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2308-13 [9215312.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1713-20 [9589681.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):361-6 [15790698.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5190-4 [15958563.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4388-92 [15958622.001]
  • [Cites] Bone Marrow Transplant. 2006 Mar;37(6):589-94 [16444283.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14085-91 [16569642.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]
  • (PMID = 19164435.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2
  • [Other-IDs] NLM/ PMC2765337
  •  go-up   go-down


8. Umesh S, Tandon A, Santosh V, Anandh B, Sampath S, Chandramouli BA, Sastry Kolluri VR: Clinical and immunohistochemical prognostic factors in adult glioblastoma patients. Clin Neuropathol; 2009 Sep-Oct;28(5):362-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.
  • OBJECTIVE: Glioblastomas are the commonest and the most malignant of all adult brain tumors, characterized by genetic instability, intratumoral histopathological variability, and unpredictable clinical behavior.
  • The utility of tumor markers that reflect their underlying biology is becoming increasingly important with respect to patient prognostication and their potential role as molecular targets of therapy is being recognized.
  • MATERIALS AND METHODS: We evaluated 54 cases of adult supratentorial glioblastomas operated over a span of 1 year, with respect to clinical features such as age, Karnofsky performance score (KPS), extent of resection, adjuvant therapy, and immunohistochemical expression of p53, EGFR (Epidermal Growth Factor Receptor) and PTEN (Phosphatase and Tensin homolog).
  • CONCLUSIONS: Our study shows that EGFR and p53 overexpression along with loss of PTEN expression are important adjuncts to clinical variables in prognosticating glioblastoma patients.
  • [MeSH-major] Glioblastoma / diagnosis. Supratentorial Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. PTEN Phosphohydrolase / metabolism. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Severity of Illness Index. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism. Young Adult


9. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R: Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res; 2005 Aug 15;11(16):5900-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Twenty-five patients with advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a phase I clinical study of a personalized peptide vaccination.
  • More importantly, significant levels of peptide-specific IgG were detected in the postvaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses.
  • The median overall survival for patients with recurrent glioblastoma multiforme in this study (n = 17) was 622 days.
  • [MeSH-major] Brain Neoplasms / immunology. Cancer Vaccines / immunology. Glioma / immunology. Peptides / immunology
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / genetics. Female. Gene Expression Regulation, Neoplastic / immunology. HLA-A Antigens / immunology. HLA-A2 Antigen / immunology. HLA-A24 Antigen. Humans. Immunoglobulin G / blood. Immunoglobulin G / cerebrospinal fluid. Leukocytes, Mononuclear / immunology. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2005 Aug 15;11(16):5663-4 [16115899.001]
  • (PMID = 16115932.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A2 Antigen; 0 / HLA-A24 Antigen; 0 / Immunoglobulin G; 0 / Peptides; 0 / RNA, Messenger
  •  go-up   go-down


10. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs; 2005 Aug;23(4):357-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
  • PURPOSE: Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for cell-cycle progression.
  • Treatment was continued until unacceptable toxicity, tumor progression, or patient withdrawal.
  • There were no grade IV hematological toxicities and no toxic deaths.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Anticonvulsants / administration & dosage. Anticonvulsants / therapeutic use. Disease-Free Survival. Drug Interactions. Female. Humans. Hypercholesterolemia / chemically induced. Infusions, Intravenous. Lymphopenia / chemically induced. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Mol Pharmacol. 1998 Nov;54(5):815-24 [9804616.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6141-5 [12414639.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):359-67 [11438483.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):169-74 [7671460.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):268-77 [12356357.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Biochem Pharmacol. 2002 Oct 1;64(7):1071-7 [12234610.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1527-32 [11245461.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5406-12 [11103942.001]
  • [Cites] Drug Resist Updat. 2001 Dec;4(6):378-91 [12030785.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):196-211 [12084351.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):331-9 [12704666.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7291-7 [12499272.001]
  • [Cites] Invest New Drugs. 2004 Nov;22(4):427-35 [15292713.001]
  • (PMID = 16012795.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455-08; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCI NIH HHS / CA / U01 CA62407-08; United States / NCI NIH HHS / CA / U01CA62421-08
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


11. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T, ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery; 2008 Mar;62(3):564-76; discussion 564-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.
  • OBJECTIVE: The influence of the degree of resection on survival in patients with glioblastoma multiforme is still under discussion.
  • METHODS: Two hundred forty-three patients with glioblastoma multiforme per protocol from the 5-aminolevulinic acid study were analyzed.
  • Prognostic factors that might cause bias regarding resection and influence survival (e.g., tumor size, edema, midline shift, location, age, Karnofsky Performance Scale score, National Institutes of Health Stroke Scale score) were used for analysis of overall survival.
  • RESULTS: Treatment bias was identified in patients with complete (n = 122) compared with incomplete resection (n = 121), i.e., younger age and less frequent eloquent tumor location.
  • Other factors, foremost preoperative tumor size, were identical.
  • Patients without residual tumor survived longer (16.7 versus 11.8 mo, P < 0.0001).
  • In multivariate analysis, only residual tumor, age, and Karnofsky Performance Scale score were significantly prognostic.
  • Reinterventions occurred marginally earlier in patients with residual tumor (6.7 versus 9.5 mo, P = 0.0582).
  • However, bias and imbalances were controllable in the cohorts available from the 5-aminolevulinic acid study so that the present data now provide Level 2b evidence (Oxford Centre for Evidence-based Medicine) that survival depends on complete resection of enhancing tumor in glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Glioblastoma / mortality. Glioblastoma / surgery. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Bias (Epidemiology). Disease-Free Survival. Female. Germany / epidemiology. Humans. Male. Middle Aged. Prevalence. Reproducibility of Results. Risk Assessment. Risk Factors. Sensitivity and Specificity. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2009 Jun;64(6):E1206; author reply E1206 [19487874.001]
  • (PMID = 18425006.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Oppel F; Brune A; Lanksch W; Woiciechowsky C; Brock M; Vesper J; Tonn JC; Goetz C; Gilsbach JM; Mayfrank L; Oertel MF; Seifert V; Franz K; Bink A; Schackert G; Pinzer T; Hassler W; Bani A; Meisel HJ; Kern BC; Mehdorn HM; Nabavi A; Brawanski A; Ullrich OW; Böker DK; Winking M; Weber F; Langenbach U; Westphal M; Kähler U; Arnold H; Knopp U; Grumme T; Stretz T; Stolke D; Wiedemayer H; Turowski B; Pietsch T; Wiestler OD; Reulen HJ; Stummer W
  •  go-up   go-down


12. Roma AA, Prayson RA: Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol; 2005 Dec;9(6):307-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression in 90 patients with glioblastoma multiforme.
  • Fascin immunohistochemical analysis was performed in 90 glioblastoma multiforme, including 53 males and 37 females (mean age, 58.3 years).
  • Nineteen tumors showed more than 75% positive staining tumor cells, 14 tumors had more than 50% to 75% staining, 23 tumors had more than 25% to 50% staining, 26 tumors had more than 5% to 25% staining, and 8 tumors had less than 5% staining.
  • In comparison, 9 of 11 low-grade astrocytomas had 50% or less staining for fascin.
  • Higher grade tumors generally expressed a greater degree of fascin staining.
  • There was no obvious correlation with the extent of staining and survival among glioblastoma multiforme.
  • Fascin may play a role in tumor cell infiltration.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioblastoma / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / metabolism. Astrocytoma / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis


13. von Lehe M, Schramm J: Gliomas of the cingulate gyrus: surgical management and functional outcome. Neurosurg Focus; 2009 Aug;27(2):E9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 7 cases (18%) the tumor was located in the posterior (parietal) part of the cingulate gyrus, and in 31 (82%) the tumor was in the anterior (frontal) part.
  • In 10 cases (26%) the glioma was solely located in the cingulate gyrus, and in 28 cases (74%) the tumor extended to the supracingular frontal/parietal cortex.
  • The authors chose an interhemispheric approach for tumor resection in 11 (29%) and a transcortical approach in 27 (71%) cases; intraoperative electrophysiological monitoring was applied in 23 (61%) and neuronavigation in 15 (39%) cases.
  • Tumors were classified as low-grade gliomas in 11 cases (29%).
  • A glioblastoma multiforme (WHO Grade IV, 10 cases [26%]) and oligoastrocytoma (WHO Grade III, 9 cases [24%]) were the most frequent histopathological results.
  • In case of resection of gliomas arising from the anterior cingulate gyrus a supplementary motor area syndrome has to be considered, particularly when the tumor extends to the supracingular cortex.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Gyrus Cinguli / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Mapping. Cerebral Cortex / surgery. Child. Female. Humans. Male. Middle Aged. Monitoring, Intraoperative. Neuronavigation. Neurosurgical Procedures / methods. Outcome Assessment (Health Care). Postoperative Complications / etiology. Preoperative Care. Seizures / etiology. Seizures / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645564.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kohshi K, Yamamoto H, Nakahara A, Katoh T, Takagi M: Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol; 2007 May;82(3):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas.
  • BACKGROUND: To reduce this complication and to enhance the radiation effect to hypoxic cells of high-grade gliomas, the authors performed noninvasive fractionated stereotactic radiotherapy (FSRT) using a Gamma unit combined with hyperbaric oxygen (HBO) therapy for the treatment of recurrent disease.
  • PATIENTS AND METHODS: Twenty-five consecutive patients who had previously received radiotherapy with chemotherapy for recurrent high-grade gliomas, including 14 patients with anaplastic astrocytoma (AA) and 11 with glioblastoma multiforme (GBM), underwent Gamma FSRT immediately after HBO therapy (2.5 atmospheres absolute for 60 min).
  • Median tumor volume was 8.7 cc (range, 1.7-159.3 cc), and the median total radiation dose was 22 Gy (range, 18-27 Gy) to the tumor margin in 8 fractions.
  • CONCLUSION: Gamma FSRT after HBO therapy appears to confer a survival benefit for patients with recurrent high-grade gliomas and warrants further investigation.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy. Hyperbaric Oxygenation. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):236-41 [10390002.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):88-92 [10638972.001]
  • [Cites] Int J Cancer. 2001 Oct 20;96(5):320-5 [11582585.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):63-7 [12758241.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] J Neurooncol. 2002 May;58(1):47-52 [12160140.001]
  • [Cites] Stereotact Funct Neurosurg. 1995;64 Suppl 1:249-57 [8584835.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):776-83; discussion 783-5 [9316038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):67-74 [12007943.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1123-8; discussion 1128-30 [10807244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • [Cites] Cancer Lett. 2001 Mar 26;164(2):149-54 [11179829.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):293-8 [10030252.001]
  • [Cites] Radiother Oncol. 1999 Nov;53(2):127-31 [10665789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):421-6 [10974456.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31 [8005794.001]
  • [Cites] Radiother Oncol. 1995 Nov;37(2):108-16 [8747934.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1045-53 [8985026.001]
  • (PMID = 17120158.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Amini A, Schmidt RH, Salzman KL, Chin SS, Couldwell WT: Glioblastoma multiforme of the pineal region. J Neurooncol; 2006 Sep;79(3):307-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme of the pineal region.
  • Glioblastoma multiforme (GBMs) tumors are exceedingly rare tumors in the pineal region.
  • Pineal region GBM seems to be a very aggressive tumor with a high rate of leptomeningeal and ependymal metastatic disease.
  • Glioblastoma should be considered in the differential diagnosis of the pineal region tumors, especially when evidence of leptomeningeal or ependymal metastatic disease is present.
  • [MeSH-major] Brain / pathology. Glioblastoma / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nausea / etiology. Tomography, X-Ray Computed. Vision Disorders / etiology. Vomiting / etiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] Arch Neurol. 1979 Nov;36(11):717-8 [508133.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):53-8 [9548342.001]
  • [Cites] Childs Nerv Syst. 1993 Nov;9(7):422-4 [8306360.001]
  • [Cites] Radiology. 1972 May;103(2):399-406 [4537183.001]
  • [Cites] Surg Neurol. 1985 Mar;23 (3):275-80 [3883555.001]
  • [Cites] Cancer. 1981 Feb 1;47(3):592-6 [6261912.001]
  • [Cites] Pediatr Neurosurg. 2003 Jun;38(6):307-23 [12759510.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):221-36 [15527093.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Jun;61(2B):468-72 [12894287.001]
  • [Cites] J Clin Neurosci. 2005 Sep;12(7):834-7 [16198924.001]
  • [Cites] J Neurosurg. 1973 Oct;39(4):455-62 [4730334.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] J Neurosurg Sci. 1990 Apr-Jun;34(2):149-50 [1965444.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 16645719.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J: Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol; 2008 May;61(6):1059-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
  • All but seven patients had Glioblastoma Multiforme (GBM), and only six cases had a Karnosfsky Performance Status (KPS) of less than 80; median age was 51 years.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharm Biomed Anal. 2002 Jun 20;29(1-2):221-8 [12062681.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8 [16467100.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):246-7 [12865910.001]
  • [Cites] Cancer Lett. 2003 Dec 8;202(1):43-51 [14643025.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):927-31 [14967452.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4648-53 [15231677.001]
  • [Cites] Pharmacol Ther. 2004 Oct;104(1):29-45 [15500907.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):8017-22 [2253244.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):309-17 [10037179.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Xenobiotica. 2005 Jan;35(1):39-50 [15788367.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):641-9 [15827338.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):337-43 [15955594.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):779-83 [12754350.001]
  • (PMID = 17694310.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCI NIH HHS / CA / U01 CA062426; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCRR NIH HHS / RR / M01-RR03186; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA62455-08; United States / NCI NIH HHS / CA / CA16672; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / U01 CA062399; United States / PHS HHS / / 022330; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCI NIH HHS / CA / U01CA62399-09; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062405; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / U01CA62399; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCRR NIH HHS / RR / M01 RR000042; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01 CA062422; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS520355; NLM/ PMC3873156
  •  go-up   go-down


17. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M: Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol; 2010 Mar;12(3):274-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
  • We assessed six-month progression-free survival (PFS) as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ).

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1454-9 [15817350.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):29-38 [17108063.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):81-3 [16944309.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5218-24 [18024867.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1987-92 [18421050.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2192-7 [18445844.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):405-10 [18484594.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3913-5 [18711176.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):579-84 [19075262.001]
  • [Cites] Curr Neurol Neurosci Rep. 2009 May;9(3):241-6 [19348713.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • (PMID = 20167815.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2940590
  •  go-up   go-down


18. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R: Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res; 2008 Dec 15;14(24):8205-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.
  • PURPOSE: Cancer stem cells (CSC) are thought to represent the population of tumorigenic cells responsible for tumor development.
  • The stem cell antigen CD133 identifies such a tumorigenic population in a subset of glioblastoma patients.
  • We conducted a prospective study to explore the prognostic potential of CSC analysis in glioblastoma patients.
  • EXPERIMENTAL DESIGN: We investigated the relationship between the in vitro growth potential of glioblastoma CSCs and patient death or disease progression in tumors of 44 consecutive glioblastoma patients treated with complete or partial tumorectomy followed by radiotherapy combined with temozolomide treatment.
  • RESULTS: In vitro CSC generation and the presence of > or = 2% CD133+ cells in tumor lesions negatively correlated with overall (P = 0.0001 and 0.02, respectively) and progression-free (P = 0.0002 and 0.01, respectively) survival of patients.
  • CONCLUSIONS: The analysis of CSCs may predict the survival of glioblastoma patients.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. Female. Glycoproteins / analysis. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Multivariate Analysis. Peptides / analysis. Prospective Studies

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biomark Med. 2010 Feb;4(1):127-8 [20387308.001]
  • (PMID = 19088037.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Peptides
  •  go-up   go-down


19. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A: Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res; 2009 Oct 1;69(19):7548-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is the most common and most malignant adult brain tumor.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Membrane Proteins / biosynthesis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Mice. Neoplasm Invasiveness. Protein Kinase C-alpha / metabolism. RNA, Small Interfering / genetics. Signal Transduction. Transfection

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773446.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / epidermal growth factor receptor VIII; 125267-21-2 / myristoylated alanine-rich C kinase substrate; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.13 / Protein Kinase C-alpha
  •  go-up   go-down


20. Bink A, Gaa J, Franz K, Weidauer S, Yan B, Lanfermann H, Seifert V, Zanella FE: Importance of diffusion-weighted imaging in the diagnosis of cystic brain tumors and intracerebral abscesses. Zentralbl Neurochir; 2005 Aug;66(3):119-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of diffusion-weighted imaging in the diagnosis of cystic brain tumors and intracerebral abscesses.
  • OBJECTIVE: It is often difficult to decide whether a cystic brain lesion is a tumor or an abscess by means of conventional MRI techniques.
  • The immediate diagnosis of a brain abscess is important for the patient's outcome.
  • PATIENTS AND METHODS: Ten patients (five men, five women) with cystic brain lesions were examined with MRI.
  • Histology revealed glioblastoma multiforme in six patients and abscess in four patients.
  • RESULTS: All brain abscesses showed markedly hyperintense signal changes on diffusion-weighted imaging, whereas the appearance of glioblastoma varied from slightly hyperintense to hypointense signal conversion.
  • The mean ADC value calculated in the six patients with cystic brain tumor was: 2.05 x 10 (-3) mm(2)/s (1.38-2.88 x 10 (-3) mm(2)/s).
  • The mean ADC value of the four patients with brain abscess was: 0.57 x 10 (-3) mm(2)/s (0.38-0.77 x 10 (-3) mm(2)/s).
  • CONCLUSION: Diffusion-weighted imaging and calculation of ADC maps constitute a helpful tool to differentiate between cystic brain tumors and brain abscesses.
  • [MeSH-major] Brain Abscess / diagnosis. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Brain / microbiology. Brain / pathology. Child. Diagnosis, Differential. Echo-Planar Imaging. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Gram-Positive Bacterial Infections / diagnosis. Gram-Positive Bacterial Infections / microbiology. Gram-Positive Bacterial Infections / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nervous System Diseases / etiology. Peptococcus

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116554.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol; 2010 Apr 20;28(12):2051-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM).
  • PATIENTS AND METHODS Patients with malignant glioma at progression after standard TMZ 150 to 200 mg/m(2) x 5 days in a 28-day cycle for three or more cycles were stratified by tumor type (anaplastic glioma group A, GBM, group B).
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioma / drug therapy
  • [MeSH-minor] Adult. Canada. Chemotherapy, Adjuvant. Disease Progression. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prospective Studies. Radiotherapy, Adjuvant. Recurrence. Time Factors. Treatment Outcome


22. Wang J, Wang X, Jiang S, Lin P, Zhang J, Wu Y, Xiong Z, Ren JJ, Yang H: Establishment of a new human glioblastoma multiforme cell line (WJ1) and its partial characterization. Cell Mol Neurobiol; 2007 Nov;27(7):831-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a new human glioblastoma multiforme cell line (WJ1) and its partial characterization.
  • (1) A new human glioblastoma multiforme (GBM) cell line, WJ1, was established from the tissue derived from a 29-year-old patient diagnosed with a grade IV GBM. (2) The WJ1 cell line has been subcultured for more than 80 passages in standard culture media without feeder layer or collagen coatings. (3) GBM cells grow in vitro with distinct morphological appearance.
  • They showed a dose- and time-dependent growth inhibition effect on the cells. (4) Orthotopic transplantation of GBM cells into athymic nude mice induced the formation of solid tumor masses about 6 weeks.
  • The cells obtained from mouse tumor masses when cultivated in vitro had the same morphology and ultrastructure as those of the initial cultures. (5) This cell line may provide a useful model in vitro and in vivo in the cellular and molecular studies as well as in testing novel therapies for human glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Culture Techniques. Cell Line, Tumor / cytology. Glioblastoma / pathology
  • [MeSH-minor] Adult. Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Cell Division. Cisplatin / pharmacology. Diterpenes, Abietane. Etoposide / pharmacology. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Karyotyping. Male. Mice. Mice, Nude. Nerve Tissue Proteins / metabolism. Nestin. Phenanthrenes / pharmacology. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Neurobiol. 2001 Aug;21(4):421-8 [11775071.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1311-6 [12649192.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):3001-4 [12782610.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):11-21 [16955220.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Anticancer Res. 1992 May-Jun;12(3):853-61 [1320358.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):117-32 [11770894.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12 (18):5288-97 [17000661.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):151-60 [9892097.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1193-214 [17113459.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4227-39 [14519650.001]
  • [Cites] Cancer Genet Cytogenet. 1998 May;103(1):46-51 [9595044.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jun;34(6):439-42 [9661044.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Neurosurgery. 2007 Feb;60(2):360-70; discussion 370-1 [17290188.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):652-9 [17432718.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Feb;26(1):22-30 [10736064.001]
  • (PMID = 17703357.001).
  • [ISSN] 0272-4340
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Diterpenes, Abietane; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Phenanthrenes; 03UUH3J385 / tanshinone; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Omura Y: Asbestos as a possible major cause of malignant lung tumors (including small cell carcinoma, adenocarcinoma & mesothelioma), brain tumors (i.e. astrocytoma & glioblastoma multiforme), many other malignant tumors, intractable pain including fibromyalgia, & some cardio-vascular pathology: Safe & effective methods of reducing asbestos from normal & pathological areas. Acupunct Electrother Res; 2006;31(1-2):61-125
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos as a possible major cause of malignant lung tumors (including small cell carcinoma, adenocarcinoma & mesothelioma), brain tumors (i.e. astrocytoma & glioblastoma multiforme), many other malignant tumors, intractable pain including fibromyalgia, & some cardio-vascular pathology: Safe & effective methods of reducing asbestos from normal & pathological areas.
  • High incidences of Small Cell Carcinoma & Adenocarcinoma of the lung, Astrocytoma & Glioblastoma Multiforme of the brain and Mesothelioma of the lung were found in those who had a high accumulation of Asbestos in the eyes and upper respiratory system (nose, larynx, trachea, etc.).
  • When measured non-invasively using the Bi-Digital O-Ring Test (BDORT), brain tumors had the highest concentration of Asbestos (0.2 approximately 2.1 mg BDORT units).
  • A small, round or ellipsoidal area, with diameter of 5 mm or less, was found near the center of every cancer tissue with a higher level of Asbestos (1 approximately 3 mg), As, Zn, Cr and Se, than in the rest of the tumor; this small area may be where the cancer initiated.
  • The author found that in the Astrocytoma and many other cancer patients, the optimal dose of DHEA produced very significant reductions of cancer cell telomere from over 1400 ng in the brain tumors (and over 900 ng in other cancers) to close to or less than 1 yg (=10(-24) g), with circulatory improvement by reduction of TXB2.
  • [MeSH-minor] Adult. Aged. Female. Humans. Inhalation Exposure / adverse effects. Lung Neoplasms / chemically induced. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Microscopy, Electron, Transmission. Middle Aged. Occupational Exposure / adverse effects


24. Iacob G, Dinca EB: Current data and strategy in glioblastoma multiforme. J Med Life; 2009 Oct-Dec;2(4):386-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current data and strategy in glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) or astrocytoma grade IV on WHO classification is the most aggressive and the most frequent of all primary brain tumors.
  • Glioblastoma is multiforme, resistant to therapeutic interventions illustrating the heterogeneity exhibited by this tumor in its every aspect, including clinical presentation, pathology, genetic signature.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Chromosome Mapping. Diagnosis, Differential. Gene Amplification. Humans. Middle Aged. Mutation. Oncogenes. PTEN Phosphohydrolase / deficiency. PTEN Phosphohydrolase / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Nat Clin Pract Neurol. 2007 Sep;3(9):E1 [17805242.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] Hum Gene Ther. 2003 Sep 1;14(13):1247-54 [12952596.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):1-8 [14712205.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):967-75 [15184253.001]
  • [Cites] J Neurosurg. 1976 Apr;44(4):442-8 [176331.001]
  • [Cites] Nature. 1980 Dec 25;288(5792):724-7 [6256643.001]
  • [Cites] Carcinogenesis. 1985 Jun;6(6):883-6 [4006075.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1988;42:187-92 [3189008.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 25;17(16):6581-90 [2780288.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):55-9 [1984507.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Sep;3(5):323-31 [1686725.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2369-79 [7673356.001]
  • [Cites] In Vivo. 1997 Nov-Dec;11(6):453-61 [9509295.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] J Neurosurg. 1963 Feb;20:122-36 [14192080.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Treat Rev. 2005 Apr;31(2):79-89 [15847978.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):198-206 [15865885.001]
  • [Cites] Neurologist. 2005 Nov;11(6):362-5 [16286879.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):337-43 [16520474.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Pediatr Neurosurg. 2007;43(3):192-201 [17409788.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Neuro Oncol. 2008 Dec;10(6):1025-34 [18667747.001]
  • [Cites] J Med Life. 2009 Oct-Dec;2(4):386-93 [20108752.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • (PMID = 20108752.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC3019011
  •  go-up   go-down


25. Rhee W, Ray S, Yokoo H, Hoane ME, Lee CC, Mikheev AM, Horner PJ, Rostomily RC: Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia; 2009 Apr 1;57(5):510-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
  • The capacity of adult human glial progenitor cells (AGPs), to proliferate and undergo multipotent differentiation, positions them as ideal candidate cells of origin for human gliomas.
  • To investigate this potential role we identified AGPs as mitotically active Olig2 cells in nonneoplastic adult human brain and gliomas.
  • Extrapolating from a mean Olig2/Mib-1 labeling index (LI) of 52% and total cell number of 100 billion, we estimated the overall prevalence of mitotic Olig2 AGPs in nonneoplastic human brain parenchyma at 10 million.
  • The vast majority of mitotic cells in Grade II and Grade III gliomas of all histologic subtypes expressed Olig2 (mean LI 75%) but rarely S100B (LI 0.6%), identifying the Olig2 cell as a distinct contributor to the proliferating cell population of human gliomas of both oligodendroglial and astrocytic lineages.
  • In the most malignant Grade IV glioma, or glioblastoma multiforme (GBM), the prevalence of Olig2/Mib-1 cells was significantly decreased (24.5%).
  • The novel framework provided by this quantitative and comparative analysis supports future studies to examine the histogenetic role of Olig2 AGPs in adult gliomas, their potential contribution to the tumor stroma and the molecular role of Olig2 in glioma pathogenesis.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18837053.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007144; United States / NINDS NIH HHS / NS / T32 NS007144-25; United States / NINDS NIH HHS / NS / T32 NS007144-28; United States / NINDS NIH HHS / NS / T32 NS 0007144
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / MIB-1 antibody; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human
  • [Other-IDs] NLM/ NIHMS77469; NLM/ PMC4415884
  •  go-up   go-down


26. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germanò A, Vita G, Tomasello F: miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol; 2009 Jul;93(3):325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.
  • Recent evidence indicates that miRNAs can function both as tumor suppressors and as oncogenes.
  • It has been demonstrated that in glioblastoma multiforme miR-21 and 221 are upregulated whereas miR-128 and 181 are downregulated.
  • Expression of miR-21, 221, 128a, 128b, 128c, 181a, 181b, 181c was studied using real-time quantitative reverse transcriptase polymerase chain reaction and northern blotting for human astrocytic tumors with different grade of malignancy. miR-21 and 221 were overexpressed in glioma samples, whereas miRNA 181b was downregulated compared with normal brain tissue. miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas.
  • This study is the first analysis of miRNAs in astrocytic tumor at different stages of malignancy.
  • The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. MicroRNAs / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Northern. Down-Regulation. Female. Gene Expression. Gene Expression Profiling. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2007 Jan;17(1):123-8 [17143488.001]
  • [Cites] Nucleic Acids Res. 2005 Nov 27;33(20):e179 [16314309.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cell Cycle. 2007 Aug 15;6(16):2005-9 [17721077.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):10-7 [10699961.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • [Cites] J Intern Med. 2008 Apr;263(4):366-75 [18298485.001]
  • [Cites] Cell. 2005 Jan 14;120(1):21-4 [15652478.001]
  • [Cites] Nature. 2000 Mar 16;404(6775):293-6 [10749213.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Science. 2001 Oct 26;294(5543):858-62 [11679671.001]
  • [Cites] Nucleic Acids Res. 2005 Oct 04;33(17):5533-43 [16204454.001]
  • [Cites] Science. 2001 Oct 26;294(5543):862-4 [11679672.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6101-12 [16682950.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] Nucleic Acids Res. 2007;35(17):5944-53 [17726050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15557-62 [16230613.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):745-6 [15944682.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nucleic Acids Res. 2005 Mar 01;33(4):1290-7 [15741182.001]
  • [Cites] Neuron. 2005 May 5;46(3):363-7 [15882632.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Semin Cell Dev Biol. 2005 Feb;16(1):49-58 [15659339.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):12688-95 [12566456.001]
  • [Cites] Science. 2005 Oct 14;310(5746):317-20 [16224024.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):363-4 [11896390.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):647-58 [17681183.001]
  • [Cites] Mol Cancer. 2007 Sep 25;6:60 [17894887.001]
  • [Cites] Brain Res. 2008 Oct 21;1236:185-93 [18710654.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):497-508 [16728577.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1133-46 [16337999.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] EMBO J. 2007 Aug 8;26(15):3699-708 [17627278.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):122-9 [18226107.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):231-5 [15531879.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):86-9 [11081512.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):974-8 [15944714.001]
  • [Cites] Development. 2005 Nov;132(21):4653-62 [16224045.001]
  • (PMID = 19159078.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN21 microRNA, human; 0 / MIRN221 microRNA, human; 0 / MIrn181 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


27. Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW: Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res; 2005 Jul 15;11(14):5292-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
  • PURPOSE: There is growing interest in developing cellular immune therapies for glioblastoma multiforme, but little is known about tumor-specific T-cell responses.
  • A glioblastoma multiforme-specific T-cell assay was developed using monocyte-derived dendritic cells to present tumor antigens from the established glioblastoma multiforme cell line U118.
  • EXPERIMENTAL DESIGN: Peripheral blood mononuclear cells (PBMC) and tumor cells were obtained from nine patients with newly diagnosed brain tumors: five glioblastoma multiforme, two oligodendroglioma, one ependymoma, and one astrocytoma.
  • PBMCs were incubated overnight with autologous tumor cells or autologous dendritic cells loaded with a U118 cell lysate, and responses were detected by IFN-gamma ELISPOT and cytokine flow cytometry assays.
  • RESULTS: PBMCs from all glioblastoma multiforme patients exhibited IFN-gamma responses to autologous tumor but not to HLA-mismatched U118 cells.
  • Glioblastoma multiforme-specific IFN-gamma responses were primarily mediated by CD8+ T cells and represented approximately 2% of total CD8+ T cells.
  • Additionally, all glioblastoma multiforme patients responded to autologous dendritic cells loaded with U118 lysate but not with low-grade astrocytoma cell lysates.
  • PBMCs from four patients with other brain tumor types and one normal donor failed to respond to U118 lysate-loaded autologous dendritic cells.
  • These data indicate that the IFN-gamma responses to U118 lysate-loaded autologous dendritic cells are glioblastoma multiforme specific.
  • Moreover, PBMCs stimulated 1 to 2 weeks with U118 lysate-loaded dendritic cells exhibited MHC class I-restricted cytotoxicity against autologous tumor cells.
  • CONCLUSIONS: Glioblastoma multiforme patients exhibit circulating tumor-specific CD8+ T cells that recognize shared tumor antigens from the glioblastoma multiforme cell line U118.
  • These data show that glioblastoma multiformes are immunogenic and support the development of immunotherapy trials.
  • [MeSH-major] Brain Neoplasms / immunology. CD8-Positive T-Lymphocytes / immunology. Dendritic Cells / immunology. Glioblastoma / immunology. Immunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antigen Presentation. Antigens, Neoplasm / analysis. Female. HLA Antigens. Humans. Immunoassay. Interferon-gamma / immunology. Leukocytes, Mononuclear / immunology. Male. Middle Aged. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033848.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA Antigens; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


28. Culicchia F, Cui JG, Li YY, Lukiw WJ: Upregulation of beta-amyloid precursor protein expression in glioblastoma multiforme. Neuroreport; 2008 Jun 11;19(9):981-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of beta-amyloid precursor protein expression in glioblastoma multiforme.
  • Glioma and glioblastoma multiforme constitute rapidly proliferating glial cell tumors whose pathogenic mechanisms are not well understood.
  • This study examined proinflammatory and neurodegenerative gene expression in five American Tissue Culture Collection glioma and glioblastoma multiforme tumor cell lines and in 14 glioma and glioblastoma samples obtained from human brain biopsy.
  • These studies suggest that glioma and glioblastoma exhibit robust upregulation of proinflammatory and neurodegenerative genetic markers that may contribute to the pathobiology, phenotype, and proliferation of glial cell growth.
  • [MeSH-major] Amyloid beta-Protein Precursor / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Up-Regulation / physiology
  • [MeSH-minor] Adult. Antigens, Human Platelet / genetics. Antigens, Human Platelet / metabolism. Cell Line, Tumor. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Female. Humans. Interleukin-1beta / metabolism. Male. Middle Aged. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521005.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Antigens, Human Platelet; 0 / Interleukin-1beta; 0 / RNA, Messenger; 0 / human platelet antigen 1b; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


29. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y, Quillien V: Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol; 2007 Jan;81(2):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
  • In this study, we investigated the mRNA and protein expression of nine tumour antigens in human glioblastoma multiforme with a view to their possible use in dendritic cell-based immunotherapy.
  • Expression of ALK, EGFRvIII, GALT3, gp100, IL-13Ralpha2, MAGE-A3, NA17-A, TRP-2 and tyrosinase were studied by real-time RT-PCR on frozen tissues using a series of 47 tumour samples from patients with glioblastoma.
  • Results were compared with non-neoplastic brain expression or glioblastoma samples with very low levels of expression near the limits of detection for EGFRvIII and MAGE-A3, as these latter two antigens were not detected in non-neoplastic brain.
  • These results point out the importance of EGFRvIII, IL-13Ralpha2 and, to a less extent gp100 and TRP-2, for developing an immunotherapy strategy against glioblastoma.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Interleukin-13 Receptor alpha2 Subunit / metabolism. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Immunotherapy. Male. Middle Aged. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. gp100 Melanoma Antigen

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2006 Oct;55(10):1209-18 [16331519.001]
  • [Cites] Lab Invest. 2001 Sep;81(9):1223-31 [11555670.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):49-56 [12115586.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4272-81 [15452186.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):301-12 [12843792.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3140-8 [7606735.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):1006-12 [12434293.001]
  • [Cites] Curr Cancer Drug Targets. 2002 Jun;2(2):91-102 [12188912.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):335-41 [10037183.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1656-62 [15477864.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):337-44 [11676393.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4980-6 [15256472.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] J Allergy Clin Immunol. 2003 Apr;111(4):677-90; quiz 691 [12704343.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1462-6 [15746047.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5226-34 [15897911.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5536-9 [7585629.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6242-4 [10841526.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):1173-83 [8642259.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Int J Oncol. 1999 Sep;15(3):481-6 [10427128.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):23-30 [16155724.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4160-7 [15930352.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Aug;31(4):384-94 [16008822.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):452-9 [15534489.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1172-9 [14520441.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Brain Tumor Pathol. 2004;21(2):53-6 [15700833.001]
  • [Cites] Brain Pathol. 2004 Jan;14(1):43-50 [14997936.001]
  • [Cites] Oncogene. 1994 Aug;9(8):2313-20 [8036013.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1036-42 [15329913.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1442-53 [10598712.001]
  • (PMID = 17004103.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / PMEL protein, human; 0 / RNA, Messenger; 0 / Trp2 protein, vertebrate; 0 / epidermal growth factor receptor VIII; 0 / gp100 Melanoma Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


30. Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST: Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer; 2009 Apr-Jun;46(2):96-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 18,820 new cases of primary central nervous system (CNS) tumors diagnosed annually in the United States, gliomas account for over 60% with 30-40% of them being glioblastoma multiforme (GBM), 10% being anaplastic astrocytoma (AA), and 10% being low grade gliomas (LGGs).
  • This is in contrast to one study from West Bengal, India, in which only 7.9% of the brain tumors were GBMs, while 46.8% were astrocytomas.
  • Of all adult primary CNS tumors, GBM is the most common and the most malignant with about 7,000 to 8,000 new cases annually in the United States.
  • Common to these approaches is the use of adjuvant radiation therapy, even as surgery alone, with or without chemotherapy, may be the mainstay for some lower grade and low-risk gliomas.
  • Specifically, the database is searched using the following keywords, with various combinations: glioma, low-grade, anaplastic, astrocytoma, oligodendroglioma, oligoastrocytoma, glioblastoma multiforme, chemotherapy, radiation, new concepts, phase III, MGMT, CDX-110 (Celldex), temozolomide, 1p/19q deletion, and bevacizumab.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Chemotherapy, Adjuvant. Evidence-Based Medicine. Glioma / therapy. Radiotherapy, Adjuvant
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / therapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / therapy. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346643.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


31. Erdoğan N, Tucer B, Mavili E, Menkü A, Kurtsoy A: Ultrasound guidance in intracranial tumor resection: correlation with postoperative magnetic resonance findings. Acta Radiol; 2005 Nov;46(7):743-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound guidance in intracranial tumor resection: correlation with postoperative magnetic resonance findings.
  • PURPOSE: To determine the inter-method agreement between intraoperative ultrasonography and postoperative contrast-enhanced magnetic resonance imaging (MRI) in detecting tumor residue.
  • Any echogenic region >5 mm in thickness extending from the surgical cavity into the brain substance was taken as the sonographic criterion for residual tumor.
  • There were four cases in whom MRI showed residue despite a negative sonography: extensive edema or Surgicel along the cavity borders (three cases with glioblastoma multiforme) and the cystic component in the vicinity of cerebrospinal fluid (a case with pituitary macroadenoma) may be the reason for the residue going undetected.
  • In a case with glioblastoma multiforme, residual enhancement was < 5 mm in thickness.
  • CONCLUSION: Intraoperative ultrasound is an effective tool for maximizing the extent of intracranial tumor resection.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / ultrasonography. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Contrast Media. Female. Gadolinium. Glioblastoma / surgery. Humans. Intraoperative Period. Male. Middle Aged. Postoperative Period. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372696.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


32. Hou LC, Bababeygy SR, Sarkissian V, Fisher PG, Vogel H, Barnes P, Huhn SL: Congenital glioblastoma multiforme: case report and review of the literature. Pediatr Neurosurg; 2008;44(4):304-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital glioblastoma multiforme: case report and review of the literature.
  • Congenital glioblastoma multiforme is a rare primary brain tumor that has a unique biology distinct from pediatric and adult variants.
  • In this report, we present a case of congenital glioblastoma with complicated management course.
  • Imaging studies revealed a large hemispheric tumor, resulting in significant midline shift suggestive of impending herniation.
  • Emergent tumor cystic fluid drainage was performed at initial presentation.
  • The patient eventually succumbed 4 months later due to aggressive tumor progression.
  • Congenital glioblastoma should be included in the differential diagnosis of infants with large intracranial tumors.
  • [MeSH-major] Glioblastoma / congenital

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18504417.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 39
  •  go-up   go-down


33. Khattab AZ, Ahmed MI, Fouad MA, Essa WA: Significance of p53 and CD31 in astrogliomas. Med Oncol; 2009;26(1):86-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Astrogliomas are the most common primary brain tumor.
  • Its progression is the result of activation of oncogenes, inactivation of tumor suppressor genes (TSGs), and expression of various growth factors.
  • Sections were stained with hematoxylin and eosin to determine the type and histological grade according to WHO (2007) classification of CNS tumors.
  • Immunostaining was done using anti p53 and CD31 and the results were measured as labeling index (LI) using image analyzer system CAS-200.
  • The expressions of p53 and CD31 were markedly increased in glioblastoma multiforme (GBM) with mean values (59.7 +/- 13.5) (P = 0.0001) and (40.7 +/- 8.9) (P = 0.001), respectively.
  • Obviously, these observations demonstrate that the co-expression and increased levels of p53 and CD31 in astrogliomas are increasing as the tumor grade is increasing.
  • CONCLUSION: The estimation of p53 and CD31 could be used as good tools to assess the grade, prognosis, and aggressiveness of the astroglial tumors.
  • Thus, the two markers can be used as adjunct to the diagnosis and stratification of the high grade from the low-grade intrinsic brain astrogliomas.
  • [MeSH-major] Antigens, CD31 / biosynthesis. Astrocytoma / metabolism. Biomarkers, Tumor. Brain Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii18-23 [15146035.001]
  • [Cites] J Neurooncol. 1999 May;43(1):19-25 [10448867.001]
  • [Cites] Clin Transl Oncol. 2006 Sep;8(9):635-41 [17005465.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):606-11 [17906460.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4223-32 [16618745.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):218-23 [11175638.001]
  • [Cites] Lab Invest. 1997 Feb;76(2):277-84 [9042164.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):513-20 [9488306.001]
  • [Cites] J Biosci. 2002 Dec;27(7):673-8 [12571372.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):123-7 [16614946.001]
  • [Cites] J Histochem Cytochem. 2006 Apr;54(4):385-95 [16234507.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Cell Biochem. 2003 Sep 1;90(1):121-37 [12938162.001]
  • [Cites] Colloids Surf B Biointerfaces. 2007 Mar 15;55(1):10-8 [17188467.001]
  • [Cites] Front Biosci. 2000 Apr 01;5:D424-37 [10762600.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):176-9 [11396636.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):19-27 [12507886.001]
  • [Cites] Mol Vis. 2004 Feb 17;10:103-11 [14978479.001]
  • [Cites] Bull Cancer. 2005 Apr;92(4):310-6 [15888387.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Pathology. 1994 Jan;26(1):1-5 [8165016.001]
  • [Cites] J Neurosci Res. 1999 Feb 15;55(4):486-95 [10723058.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):34-44 [10640274.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4747-53 [9494601.001]
  • (PMID = 18821037.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


34. Lau CJ, Koty Z, Nalbantoglu J: Differential response of glioma cells to FOXO1-directed therapy. Cancer Res; 2009 Jul 1;69(13):5433-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common adult primary brain tumors, and the most malignant form, glioblastoma multiforme, is invariably fatal.
  • The phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is altered in most glioblastoma multiforme.
  • Our results indicate that targeting FOXO1, which is at the convergence point of several growth factor receptor tyrosine kinase pathways, can effectively induce glioma cell death and inhibit tumor growth.
  • [MeSH-major] Brain Neoplasms / pathology. Forkhead Transcription Factors / drug effects. Glioma / pathology
  • [MeSH-minor] Adenoviridae / genetics. Animals. Cell Cycle / drug effects. Cell Cycle / genetics. Cell Line, Tumor. Cyclin D1 / physiology. Cyclin D2. Cyclin-Dependent Kinase 2 / antagonists & inhibitors. Cyclins / physiology. DNA Repair. Disease Models, Animal. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Neovascularization, Pathologic / prevention & control. Phosphorylation


35. Smith KA, Ashby LS, Gonzalez LF, Brachman DG, Thomas T, Coons SW, Battaglia M, Scheck A: Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg; 2008 Dec;109 Suppl:106-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme.
  • OBJECT: The purpose of this study was to determine whether increased local control and improved survival can be achieved in patients with glioblastoma multiformes (GBMs) who undergo aggressive resection, Gliadel wafer implantation, Gamma Knife radiosurgery (GKS), and fractionated radiotherapy (RT) as the initial treatment.
  • To estimate the potential effects on the DNA repair mechanism, tumor tissue was analyzed with methylation-specific polymerase chain reaction analysis and immunohistochemical assays for MGMT gene promoter methylation and protein expression.
  • Local tumor control was achieved in 53% of patients, and local failure occurred in 47%.
  • Aggressive local tumor control with these multimodal therapies should be approached judiciously for a select group of high performance patients and the probability of developing symptomatic radionecrosis requiring surgery should be anticipated and fully disclosed to patients who undergo this treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / therapy. Carmustine / administration & dosage. Glioblastoma / therapy. Radiosurgery. Radiotherapy, Conformal
  • [MeSH-minor] Adult. Aged. Biocompatible Materials / administration & dosage. Cohort Studies. Combined Modality Therapy. Decanoic Acids / administration & dosage. Dose Fractionation. Drug Implants. Female. Humans. Male. Middle Aged. Polyesters / administration & dosage. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2009 Jun;110(6):1323-4
  • [ErratumIn] J Neurosurg. 2009 Sep;111(3):639. Gonzalez, Fernando [corrected to Gonzales, L Fernando]
  • (PMID = 19123896.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biocompatible Materials; 0 / Decanoic Acids; 0 / Drug Implants; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


36. Glantz M, Kesari S, Recht L, Fleischhack G, Van Horn A: Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay. Semin Oncol; 2009 Aug;36(4 Suppl 2):S17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM), the most common malignant primary brain tumor in adults, carries a poor prognosis, with median survival generally less than 1 year.
  • Although initial therapy often eradicates the bulk of the tumor, disease recurrence, usually within 2 cm of the original tumor, is almost inevitable.
  • An increasing body of preclinical data suggests that these cells may correspond to stem cells derived from the subventricular zone (SVZ), which migrate to tumor sites and contribute to glioma growth and recurrence.
  • Therapeutic targeting of SVZ stem cell populations via cerebrospinal fluid (CSF)-directed therapy may provide a means for limiting tumor recurrence.
  • This approach has proved successful in the treatment of medulloblastoma, another brain tumor thought to be derived from stem cells.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / methods. Humans. Injections, Spinal. Neoplastic Stem Cells. Research Design

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19660679.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Agnihotri S, Wolf A, Picard D, Hawkins C, Guha A: GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system. Oncogene; 2009 Aug 27;28(34):3033-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system.
  • The GATA transcription factors consist of six family members, which bind to the consensus DNA-binding element, W-GATA-R, and are poorly characterized in the central nervous system (CNS).
  • Using retroviral gene trapping on transgenic mouse glioma models, we identified GATA6 to be a novel tumor suppressor gene in glioblastoma multiforme.
  • We now show GATA4, a family member of GATA6, to be expressed in the neurons and glia of normal murine and human embryonic and adult CNS.
  • Furthermore, GATA4 expression was lost in a panel of human malignant astrocytoma cell lines.
  • Collectively, we show that GATA4 is expressed in the embryonic and adult CNS and acts as a negative regulator of astrocyte proliferation and growth.
  • [MeSH-major] Apoptosis. Astrocytes / physiology. Brain / cytology. GATA4 Transcription Factor / physiology
  • [MeSH-minor] Animals. Cell Cycle. Cell Proliferation. Cells, Cultured. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Humans. Mice. Transforming Growth Factor beta / pharmacology. Tumor Suppressor Protein p53 / physiology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543315.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / Gata4 protein, mouse; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


38. Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, Mäcke H, Müller-Brand J, Merlo A: Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study. J Neurooncol; 2010 Oct;100(1):129-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study.
  • Complete surgical resection beyond tumor margins cannot be achieved in glioblastoma multiforme (GBM) because of infiltrative nature.
  • In several cancers, neoadjuvant treatment has been implemented to reduce the risk of tumor cell spreading during resection.
  • In GBM, the objective of a neoadjuvant approach is reduction of tumor cells within the main tumor mass and beyond in the infiltration zone.
  • In a previous study with recurrent gliomas, we showed that local intratumoral injection of radiolabeled DOTAGA-substance P substantially inhibited further growth and led to radionecrotic transformation of the tumor (CCR 2006).
  • The high extent of resection and concomitant irradiation of tumor cells in the infiltration zone may be prognostically relevant.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Heterocyclic Compounds, 1-Ring / therapeutic use. Neoadjuvant Therapy / methods. Substance P / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Diagnostic Imaging / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Organometallic Compounds. Radiopharmaceuticals / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2157-65 [10873064.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(5):303-20 [10591819.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Expert Rev Neurother. 2006 Aug;6(8):1199-209 [16893347.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3843-50 [16778112.001]
  • [Cites] Adv Tech Stand Neurosurg. 2004;29:229-63 [15035340.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1388-95 [17265035.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1021-34 [16897272.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3862-72 [11078500.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1362-8 [9396606.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] J Neurosurg. 2004 Dec;101(6):1004-11 [15597761.001]
  • [Cites] Neurosurg Focus. 2005 Apr 15;18(4):e12 [15844864.001]
  • [Cites] Oncologist. 2006 Jun;11(6):574-89 [16794237.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Int J Cancer. 1997 May 29;71(5):810-6 [9180150.001]
  • [Cites] Ernst Schering Res Found Workshop. 2005;(49):43-72 [15524210.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):786-92 [7790112.001]
  • [Cites] Neurosurg Clin N Am. 2005 Jan;16(1):xi-xiii [15561527.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):412-23 [17622648.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):486-93 [11914886.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1025-33 [10353735.001]
  • [Cites] Breast. 2006 Feb;15 Suppl 1:S3-13 [16500235.001]
  • [Cites] Neuro Oncol. 2008 Apr;10 (2):216-22 [18314417.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):937-49 [17171643.001]
  • [Cites] Int J Rehabil Res. 2005 Jun;28(2):135-9 [15900183.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Aug;43(8):391-5 [12968806.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2117-23 [10570440.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:57-61 [11143263.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6 [18496181.001]
  • [Cites] J Gene Med. 2004 Aug;6(8):937-47 [15293352.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 20217458.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heterocyclic Compounds, 1-Ring; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; 0 / substance P, 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-arginyl(1)-; 33507-63-0 / Substance P
  •  go-up   go-down


39. Ali K, Lu Y, Das U, Sharma RK, Wiebe S, Meguro K, Sadanand V, Fourney DR, Vitali A, Kelly M, May T, Gomez J, Pellerin E: Biomolecular diagnosis of human glioblastoma multiforme using Synchrotron mid-infrared spectromicroscopy. Int J Mol Med; 2010 Jul;26(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomolecular diagnosis of human glioblastoma multiforme using Synchrotron mid-infrared spectromicroscopy.
  • Glioblastoma multiforme (GBM) is one of the most malignant human tumors, with a uniformly poor outcome.
  • One obstacle in curing malignant brain tumors is the limitation of conventional light microscopy in detecting microscopic residual tumor in biopsy samples from the perimeter of the surgically resected tumor.
  • We further refined the identification of GBM tumor tissue at the sub-cellular level, utilising the technique of Synchrotron, sourced mid-infrared (mid-IR) spectromicroscopy.
  • Paired, thin (5 microm) cryosections of snap-frozen human GBM tumor samples removed at elective surgery were mounted on glass slides (hematoxylin and eosin-stained tissue section) and calcium fluoride (CaF2) windows (unstained tissue section for transmission spectromicroscopy), respectively.
  • Concordance of tumor bearing areas identified in the stained section with the unstained IR tissue section was confirmed by the pathologist of the study.
  • Compared with molecular signatures obtained from normal control brain tissue, unique spectroscopic patterns were detected in GBM tumor samples from 6 patients.
  • False color images of 5 clusters obtained by HCA identified dominant clusters corresponding to tumor tissue.
  • Corroboration of these findings in a larger number of GBM may allow for more precise identification of these and other types of brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Spectrophotometry, Infrared / methods. Synchrotrons
  • [MeSH-minor] Adult. Aged. Calcium Fluoride / chemistry. Child. Cluster Analysis. Cryoultramicrotomy / methods. Female. Histocytochemistry / methods. Humans. Lipids / analysis. Lipids / chemistry. Male. Middle Aged. Proteins / analysis. Proteins / chemistry

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM FLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514416.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Lipids; 0 / Proteins; O3B55K4YKI / Calcium Fluoride
  •  go-up   go-down


40. Loh KC, Willert J, Meltzer H, Roberts W, Kerlin B, Kadota R, Levy M, White G, Geddis A, Schiff D, Martin L, Yu A, Kung F, Spear MA: Temozolomide and radiation for aggressive pediatric central nervous system malignancies. J Pediatr Hematol Oncol; 2005 May;27(5):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and radiation for aggressive pediatric central nervous system malignancies.
  • This study describes the outcomes of children treated with combinations of temozolomide and radiation therapy for various aggressive central nervous system malignancies.
  • Toxicities observed included low-grade neutropenia, thrombocytopenia, and lymphopenia.
  • The combination of temozolomide and radiotherapy appears to be well tolerated in a variety of treatment schemas for aggressive pediatric central nervous system malignancies.
  • This information is of particular use in designing future studies, given the recent positive results in a randomized study examining the use of temozolomide concomitant with radiation in the treatment of adult glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891559.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


41. Silvestre DC, Gil GA, Tomasini N, Bussolino DF, Caputto BL: Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice. PLoS One; 2010;5(3):e9544
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice.
  • Herein we examined phospholipid synthesis status in brain tumors from human patients and from NPcis mice, an animal model of the human disease Neurofibromatosis Type 1 (NF1).
  • PRINCIPAL FINDINGS: In human samples, c-Fos expression was at the limit of detection in non-pathological specimens, but was abundantly expressed associated to ER membranes in tumor cells.
  • This was also observed in CNS of adult tumor-bearing NPcis mice but not in NPcis fos(-/-) KO mice.
  • A glioblastoma multiforme and a malignant PNS tumor from a NF1 patient (MPNST) showed a 2- and 4- fold c-Fos-dependent phospholipid synthesis activation, respectively.
  • They also disclose this protein as a potential target for controlling tumor growth in the nervous system.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Cytoplasm / metabolism. Proto-Oncogene Proteins c-fos / biosynthesis
  • [MeSH-minor] Animals. Brain / metabolism. Brain / pathology. Cell Proliferation. Disease Models, Animal. Endoplasmic Reticulum / metabolism. Genotype. Humans. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Neurofibromatosis 1 / metabolism. Phosphorylation

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] J Neurosci Res. 2009 Aug 1;87(10):2273-81 [19267420.001]
  • [Cites] Neurochem Res. 2000 Jan;25(1):153-62 [10685615.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Genes Dev. 2000 Nov 1;14(21):2695-700 [11069886.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 12;280(1):9-13 [11162469.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] FASEB J. 2001 Mar;15(3):556-8 [11259365.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4369-78 [11390664.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Apr 30;135(1-2):71-7 [11978395.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Trends Mol Med. 2003 Jan;9(1):19-23 [12524206.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):371-81 [14667504.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1881-94 [14767061.001]
  • [Cites] Glia. 1989;2(4):223-30 [2527821.001]
  • [Cites] Nature. 1989 Aug 17;340(6234):568-71 [2505081.001]
  • [Cites] J Neurochem. 1990 Dec;55(6):1855-60 [2230799.001]
  • [Cites] Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57 [1751545.001]
  • [Cites] Neuron. 1992 Jan;8(1):13-23 [1730004.001]
  • [Cites] Cell. 1992 Nov 13;71(4):577-86 [1423615.001]
  • [Cites] Nature. 1992 Dec 24-31;360(6406):741-5 [1465144.001]
  • [Cites] Trends Neurosci. 1995 Feb;18(2):66-7 [7537412.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):507-13 [8637706.001]
  • [Cites] J Neurosci Res. 1996 Jan 1;43(1):93-8 [8838579.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):10-5 [9685570.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):1228-35 [10461916.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Aug 1;214(3):263-9 [16473383.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3551-8 [17160021.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10631-4 [18006802.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):31163-71 [18784083.001]
  • [Cites] J Neurosci Res. 2009 Mar;87(4):857-65 [18951474.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1127-30 [19407794.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 20209053.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-fos
  • [Other-IDs] NLM/ PMC2832012
  •  go-up   go-down


42. Martinez R, Schackert HK, Appelt H, Plaschke J, Baretton G, Schackert G: Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme. J Cancer Res Clin Oncol; 2005 Feb;131(2):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme.
  • PURPOSE: Genetic instability is a hallmark of glioblastoma multiforme (GBM).
  • RESULTS: MSI was observed in six GBMs (5.5%) and it was more frequent in GBMs with a previous lower grade astrocytoma (18.8% vs. 3.2%).
  • Among MSI(+) GBMs, one tumor corresponded to the GBM molecular type 1 (p53 mutation, no EGFR amplification), another tumor to type 2 (wild-type p53, EGFR amplification), and four tumors to neither type (wild-type p53, no EGFR amplification).
  • [MeSH-major] Base Pair Mismatch / genetics. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioblastoma / genetics. Glioblastoma / pathology. Microsatellite Repeats / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Transformation, Neoplastic. DNA Damage. DNA Repair. Female. Humans. Immunohistochemistry. Male. Middle Aged. Phenotype


43. Gömöri E, Halbauer JD, Kasza G, Varga D, Horvath Z, Komoly S: Glioblastoma multiforme with an unusual location and clinical course. Clin Neuropathol; 2009 May-Jun;28(3):165-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme with an unusual location and clinical course.
  • We present a unique case of a brain tumor patient with atypical location and progression.
  • Postmortally, formalin-fixed brain demonstrated that the main tumor mass was located in the fornix, infiltrating the ventricular system and disseminating over the cortex, cerebellum and spinal cord.
  • The authors recommend closer scrutiny of psychiatric patients presenting CNS symptomatology, negative MRI, CT and CSF.
  • [MeSH-major] Brain Neoplasms / diagnosis. Diagnostic Errors. Glioblastoma / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Accidents, Traffic. Adult. Anxiety / etiology. Fatal Outcome. Humans. Male. Mood Disorders / etiology. Stress Disorders, Post-Traumatic

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537131.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A, Akter M, Hayashida Y, Toya R, Oya N, Awai K, Iyama K, Kuratsu JI, Yamashita Y: Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol; 2008 Sep;29(8):1505-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study.
  • BACKGROUND AND PURPOSE: Although the prognostic value of perfusion MR imaging in various gliomas has been investigated, that in high-grade astrocytomas alone has not been fully evaluated.
  • The purpose of this study was to evaluate retrospectively whether the tumor maximum relative cerebral blood volume (rCBV) on pretreatment perfusion MR imaging is of prognostic value in patients with high-grade astrocytoma.
  • MATERIALS AND METHODS: Between January 1999 and December 2002, 49 patients (30 men, 19 women; age range, 23-76 years) with supratentorial high-grade astrocytoma underwent MR imaging before the inception of treatment.
  • The patient age, sex, symptom duration, neurologic function, mental status, Karnofsky Performance Scale, extent of surgery, histopathologic diagnosis, tumor component enhancement, and maximum rCBV were assessed to identify factors affecting survival.
  • RESULTS: The maximum rCBV was significantly higher in the 31 patients with glioblastoma multiforme than in the 18 with anaplastic astrocytoma (P < .03).
  • CONCLUSION: The maximum rCBV at pretreatment perfusion MR imaging is a useful clinical prognostic biomarker for survival in patients with high-grade astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / mortality. Brain Neoplasms / diagnosis. Brain Neoplasms / mortality. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Japan / epidemiology. Longitudinal Studies. Male. Middle Aged. Prevalence. Prognosis. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556364.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB: Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol; 2008 Jul;88(3):339-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) are morphologically heterogeneous tumors, with varying amounts of necrosis, and edema.
  • Previous studies have shown that treatments incorporating the VEGF antibody bevacizumab can reduce edema and tumor burden in GBM.
  • Therefore we sought to (1) determine the time course of change in necrosis, tumor, and edema volume in patients who respond to bevacizumab regimen treatment and (2) determine if GBM that progress following a response to bevacizumab regimen treatment are morphologically different from their appearance at prior tumor progression.
  • Therefore, we retrospectively assessed tumor, necrosis, and edema volumes on MRI scans from 15 patients with recurrent GBM who responded to bevacizumab regimen treatment, and had extended (>7 month) follow-up.
  • We found that the median time to best tumor response was 158 days (range, 16-261, SD = 63).
  • The median best response was 72.1% reduction in tumor volume and 72.8% reduction in peritumoral edema.
  • The relative reduction of edema and necrosis was sustained, even in patients (n = 7) who developed tumor progression.
  • Thus the mean ratio of edema-to-tumor volume at progression on bevacizumab regimen treatment was 38.4% lower than that for the same tumors seen on progression scans following prior chemotherapy.
  • The percentage of necrotic tumor also was diminished following progression on bevacizumab regimen treatment.
  • These findings illustrate the time course of changes in edema and tumor volume with prolonged bevacizumab regimen treatment, and support the conclusion that the morphology of recurrent GBM following bevacizumab regimen therapy is distinct from that on other chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Brain Neoplasms / pathology. Glioblastoma / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Retrospective Studies. Time

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2592-8 [17473188.001]
  • [Cites] Trends Mol Med. 2007 Jun;13(6):223-30 [17462954.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):551-7 [11208850.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):156-65 [16533757.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:127-9 [12401678.001]
  • [Cites] Neurology. 2004 Aug 10;63(3):535-7 [15304589.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Radiographics. 1996 Nov;16(6):1413-38; quiz 1462-3 [8946545.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6 [17236958.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):38-46 [16443946.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74 [16286386.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 18389177.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


46. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science; 2008 Sep 26;321(5897):1807-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated genomic analysis of human glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer.
  • To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples.
  • These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854877 for PMID:18772396 [PharmGKB] .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3812-4 [12824425.001]
  • [Cites] Science. 2008 Aug 15;321(5891):956-60 [18599741.001]
  • [Cites] J Comput Chem. 2004 Oct;25(13):1605-12 [15264254.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] J Comp Neurol. 1973 Mar 15;148(2):211-6 [4700508.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Biotechniques. 2008 Jul;45(1):81-94 [18611170.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):508-12 [11981567.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):210-2 [7550353.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2495-9 [8669813.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] Mol Biol Evol. 1998 Dec;15(12):1674-84 [9866202.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):372-7 [15605984.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Nat Methods. 2006 Jan;3(1):31-3 [16369550.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):360-70 [16575211.001]
  • [Cites] Methods Mol Biol. 2007;356:319-50 [16988414.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):709-14 [17050665.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Mol Cell Biochem. 2007 Aug;302(1-2):27-34 [17646934.001]
  • [Cites] Genome Res. 2007 Sep;17(9):1304-18 [17693572.001]
  • [Cites] Free Radic Biol Med. 2007 Oct 15;43(8):1197-207 [17854715.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8 [18337506.001]
  • [Cites] Cell. 2008 May 2;133(3):523-36 [18423832.001]
  • [Cites] Nat Methods. 2008 Jul;5(7):621-8 [18516045.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • (PMID = 18772396.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043460-27; United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R37 CA043460-27; United States / NINDS NIH HHS / NS / NS052507; United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / R37 CA057345-13; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R37 CA057345-18; United States / NCI NIH HHS / CA / CA09547; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / R01 CA140316; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA062924-160017; United States / NCI NIH HHS / CA / R01 CA121113-04; United States / NCI NIH HHS / CA / CA057345-13; United States / NCI NIH HHS / CA / P50 CA062924-160017; United States / NCI NIH HHS / CA / CA057345-17; United States / NCI NIH HHS / CA / CA11898; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / CA057345-18; United States / NCI NIH HHS / CA / R37 CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345; United States / NINDS NIH HHS / NS / 5P50-NS-20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ NIHMS105586; NLM/ PMC2820389
  •  go-up   go-down


47. Bambery KR, Schültke E, Wood BR, Rigley MacDonald ST, Ataelmannan K, Griebel RW, Juurlink BH, McNaughton D: A Fourier transform infrared microspectroscopic imaging investigation into an animal model exhibiting glioblastoma multiforme. Biochim Biophys Acta; 2006 Jul;1758(7):900-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Fourier transform infrared microspectroscopic imaging investigation into an animal model exhibiting glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is a highly malignant human brain tumour for which no cure is available at present.
  • C6 cell glioma in the adult rat is a frequently used and well accepted animal model for the malignant human glial tumour.
  • We have used a "Stingray" FTIR imaging spectrometer to analyse and compare the compositions of coronal brain tissue sections of a tumour-bearing animal and those from a healthy animal.
  • We have found that the tumour tissue has a characteristic chemical signature, which distinguishes it from tumour-free brain tissue.
  • The results indicate that FTIR imaging analysis could become a valuable analytic method in brain tumour research and possibly in the diagnosis of human brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Diagnostic Imaging / methods. Glioblastoma / diagnosis. Spectroscopy, Fourier Transform Infrared
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Disease Models, Animal. Male. Proteins / analysis. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16815240.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins
  •  go-up   go-down


48. Colavolpe C, Guedj E, Metellus P, Barrie M, Figarella-Branger D, Mundler O, Chinot O: FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. J Neurooncol; 2008 Oct;90(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report.
  • True multicentric glioblastoma multiforme (GBM) is rare and consists of separate distinct tumors in different cerebral lobes or hemispheres without any apparent route of dissemination.
  • In this paper, we report on the case of a man with bifocal tumor in the right frontal and temporal lobes who underwent FDG-PET imaging.
  • The diagnosis of glioblastoma was confirmed by neuropathological examination in both cases but with much higher immunohistochemical expression of O(6)-methylguanine-DNA-methyltransferase (MGMT) in the temporal lesion.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / pathology. Fluorodeoxyglucose F18. Glioblastoma / diagnostic imaging. Glioblastoma / pathology. Positron-Emission Tomography
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease Progression. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Rev. 2003 Oct;26(4):275-9 [12898393.001]
  • [Cites] Surg Neurol. 1994 Jul;42(1):14-8 [7940089.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14 (1):123-9 [18172261.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Neurosurgery. 1983 Aug;13(2):170-5 [6310436.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Dec;106(1):38-40 [14643915.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):509-61 [8392523.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Aug;30(8):604-9 [1703639.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):157-63 [11206011.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1279-92 [11943713.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] J Neurosurg. 1963 Feb;20:122-36 [14192080.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18568292.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


49. Jain D, Sharma MC, Sarkar C, Deb P, Gupta D, Mahapatra AK: Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion. Brain Tumor Pathol; 2006 Oct;23(2):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion.
  • Astrocytic lesions, the most common, include 10 pilocytic astrocytomas (PA), 29 diffuse astrocytomas (DA), 11 anaplastic astrocytomas (AA), and 7 glioblastoma multiforme (GBM).
  • [MeSH-major] Biopsy / methods. Brain / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Stereotaxic Techniques
  • [MeSH-minor] Adolescent. Adult. Aged. Aging. Child. Coloring Agents. Eosine Yellowish-(YS). Female. Fluorescent Dyes. Hematoxylin. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Paraffin Embedding. Reproducibility of Results. Retrospective Studies. Sex Characteristics. Tissue Fixation. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095122.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Fluorescent Dyes; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


50. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD: Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol; 2006 Aug 1;24(22):3651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
  • The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG).
  • [MeSH-major] Anticonvulsants / administration & dosage. Anticonvulsants / pharmacology. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Enzyme Induction / drug effects. Glioblastoma / drug therapy. Glioma / drug therapy. Quinolones / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Drug Administration Schedule. Epilepsy / etiology. Epilepsy / prevention & control. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. North America. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA6242; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455-08; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01CA62399; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / U01CA62422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib
  •  go-up   go-down


51. Chiba Y, Hashimoto N, Tsuboi A, Rabo C, Oka Y, Kinoshita M, Kagawa N, Oji Y, Sugiyama H, Yoshimine T: Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol; 2010 Apr;27(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients.
  • The use of Wilms' tumor 1 (WT1) immunotherapy is considered to be an innovative approach for the treatment of malignant gliomas.
  • In this article, we investigated the role of WT1 protein expression level (score 1-4) and MIB-1 staining index in predicting survival outcome after therapy in patients with recurrent or progressive glioblastoma multiforme.
  • Tumor samples from 37 patients enrolled in a phase II clinical trial on WT1 immunotherapy were immunohistochemically analyzed for WT1 levels and MIB-1 index.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Glioblastoma / diagnosis. Glioblastoma / therapy. Immunotherapy. Ki-67 Antigen / analysis. Staining and Labeling. WT1 Proteins / administration & dosage. WT1 Proteins / analysis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425045.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / WT1 Proteins
  •  go-up   go-down


52. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol; 2009 Feb 1;27(4):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
  • PURPOSE: This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma.
  • After XRT, the erlotinib dose was escalated until patients developed tolerable grade 2 rash or until the maximum allowed dose was reached.
  • Molecular markers of epidermal growth factor receptor (EGFR), EGFRvIII, phosphatase and tensin homolog (PTEN), and methylation status of the promotor region of the MGMT gene were analyzed from tumor tissue.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9 [16626884.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 May;61(6):1059-67 [17694310.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1442-53 [10598712.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):207-18 [10454198.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1454-9 [15817350.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • (PMID = 19075262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / 2 P50 CA097257
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride
  • [Other-IDs] NLM/ PMC2645859
  •  go-up   go-down


53. Prayson NF, Angelov L, Prayson RA: Microscopic thrombi in glioblastoma multiforme do not predict the development of deep venous thrombosis. Ann Diagn Pathol; 2009 Oct;13(5):291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic thrombi in glioblastoma multiforme do not predict the development of deep venous thrombosis.
  • Patients with glioblastoma multiforme (GBM) are known to be at risk for hypercoagulable events.
  • The purpose of this study was to assess whether there is a relationship between the number of thrombi identified microscopically at the time of tumor resection and the subsequent development of extremity deep venous thrombosis (DVT).
  • A retrospective review of 96 patients (53 men and 43 women; age range, 21-92 years; mean age, 60.2 years) with GBM (World Health Organization grade IV) was carried out.
  • Thrombi were counted (number of thrombi/blood vessels evaluated/10 high-power fields) in nonnecrotic areas of the resected tumor and correlated with a variety of clinical and pathological parameters, including the development of postoperative DVT, as detected by extremity ultrasound.
  • Eighty-one patients died of tumor (survival, 1-66 months; mean, 11.0 months), 12 patients were alive at last known follow-up (mean, 23 months), and 3 patients were lost to follow-up.
  • Of patients with DVT, 27 patients died of tumor (survival, 1-47 months; mean, 11.0 months), 3 patients were alive (18, 20, and 21 months), and 1 patient was lost to follow-up.
  • There was no correlation between the number of microscopic thrombi and the percentage of resected tumor that was necrotic (range, <5%-90%), presence of palisaded necrosis (36.8% of tumors), presurgical (mean, 78.3) or postsurgical (mean, 75.5) Karnofsky performance scores, or survival (mean, 8.9 months in patients with no microscopic thrombi vs 11.5 months in patients with thrombi).
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Venous Thrombosis / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Ohio / epidemiology. Prognosis. Retrospective Studies. Survival Rate. Ultrasonography. Young Adult


54. Zukiel R, Nowak S, Wyszko E, Rolle K, Gawronska I, Barciszewska MZ, Barciszewski J: Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther; 2006 Aug;5(8):1002-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of human brain tumor with interference RNA specific for tenascin-C.
  • Glioblastoma multiforme (GBM) accounts for approximately 12-15% of intracranial neoplasms.
  • The GBM remains refractory to therapy because of tumor heterogeneity, local invasion, and non-uniform vascular permeability to drugs.
  • Patients with GBM have the median survival of approximately 8-10 months, and for those cases where tumor recurs, the average time of tumor progression after therapy is only eight weeks.
  • Recently, tenascin-C (TN-C) as a dominant epitope in glioblastoma has been discovered.
  • It was found that the intensity of TN-C staining correlates with the tumor grade and that the strongest staining indicates poor prognosis.
  • [MeSH-major] Brain Neoplasms / therapy. Gene Expression Regulation, Neoplastic. Gene Silencing. Glioblastoma / therapy. RNA, Small Interfering / pharmacology. Tenascin / genetics
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16775434.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Tenascin
  •  go-up   go-down


55. Singh PK, Singh VK, Tomar J, Azam A, Gupta S, Kumar S: Spinal glioblastoma multiforme: unusual cause of post-traumatic tetraparesis. J Spinal Cord Med; 2009;32(5):583-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal glioblastoma multiforme: unusual cause of post-traumatic tetraparesis.
  • BACKGROUND/OBJECTIVE: Glioblastoma multiforme (GBM) is the most common glial cell tumor of the adult brain.
  • A magnetic resonance scan showed the typical appearance of a high-grade intramedullary tumor with fusiform expansion of the entire cervical cord.
  • CONCLUSIONS: This presentation of GBM of the cervical cord is rare; an intramedullary tumor should be considered when minor cervical trauma results in disproportionate neurologic deficit.
  • [MeSH-major] Glioblastoma / complications. Quadriplegia / etiology. Quadriplegia / therapy. Spinal Neoplasms / complications
  • [MeSH-minor] Decompression, Surgical. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Radiotherapy. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] No Shinkei Geka. 1985 Mar;13(3):301-5 [2989721.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):489-94 [1701860.001]
  • [Cites] No Shinkei Geka. 1992 Jan;20(1):85-9 [1310803.001]
  • [Cites] Arch Neurol. 1978 Apr;35(4):244-5 [205201.001]
  • [Cites] Radiology. 1965 Mar;84:401-8 [14283212.001]
  • [Cites] Spinal Cord. 2005 Sep;43(9):565-7 [15838531.001]
  • [Cites] Acta Oncol. 2006;45(1):87-90 [16464801.001]
  • [Cites] J Neurosurg Spine. 2007 Dec;7(6):656-9 [18074692.001]
  • [Cites] Rinsho Shinkeigaku. 1995 Nov;35(11):1235-40 [8720335.001]
  • (PMID = 20025156.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2792466
  •  go-up   go-down


56. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res; 2006 Aug 15;12(16):4899-907
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
  • Fifty-five non-EIAED patients (34 glioblastoma multiforme and 21 anaplastic glioma) enrolled in the phase II component.
  • There were 2 partial response and 6 stable disease among glioblastoma multiforme patients and 0 partial response and 5 stable disease among anaplastic glioma patients.
  • Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Piperazines / adverse effects. Piperazines / therapeutic use. Pyrimidines / adverse effects. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Anticonvulsants / therapeutic use. Benzamides. Drug Interactions. Female. Genotype. Humans. Imatinib Mesylate. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914578.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03CA102974-02
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


57. Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Sköld K: An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand; 2008 Mar;117(3):191-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme.
  • Objectives - To explore the use of boron neutron capture therapy (BNCT) for patients with glioblastoma multiforme (GBM), recurring after surgery and conventional radiotherapy (photon radiotherapy).
  • BNCT was well tolerated and quality of life remained stable until tumor progression for all 12 patients.
  • No correlation was found between survival times and minimum tumor dose and number of radiation fields.
  • Conclusions - Boron neutron capture therapy, with the prolonged procedure for infusion, is at least as effective as other radiation therapies for recurrent GBM and is delivered in one treatment session, with low radiation dose to the healthy brain.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Body Weight. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297764.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


58. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H, Yoshimine T: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg; 2008 May;108(5):963-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
  • OBJECT: The object of this study was to investigate the safety and clinical responses of immunotherapy targeting the WT1 (Wilms tumor 1) gene product in patients with recurrent glioblastoma multiforme (GBM).
  • Tumor size, which was obtained by measuring the contrast-enhanced area on magnetic resonance images, was determined every 4 weeks.
  • Patients who achieved an effective response continued to be vaccinated until tumor progression occurred.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Glioblastoma / therapy. Nuclear Proteins / immunology
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Humans. Injections, Intradermal. Male. Middle Aged. Treatment Outcome. Vaccination

  • Genetic Alliance. consumer health - Glioblastoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447714.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Nuclear Proteins; 0 / WTAP protein, human
  •  go-up   go-down


59. Dresemann G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol; 2005 Oct;16(10):1702-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
  • BACKGROUND: Grade IV malignancies of the brain, such as glioblastoma multiforme (GBM), are associated with a dismal prognosis.
  • Autocrine and paracrine loops of platelet-derived growth factor (PDGF) signaling, as well as other signal transduction pathways, have been postulated to play a role in glioblastoma transformation, and molecules involved in these pathways can potentially serve as targets for therapeutic inhibitory agents.
  • Imatinib, an inhibitor of PDGF receptors alpha and beta, as well as other selected tyrosine kinases, is indicated for treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST).
  • PATIENTS AND METHODS: We tested the combination of hydroxyurea and imatinib in 30 grade IV progressive GBM patients refractory to chemo- and radiotherapy.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033874.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


60. Balzarotti M, Fontana F, Marras C, Boiardi A, Croci D, Ciusani E, Salmaggi A: In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res; 2006;16(5):245-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.
  • In the last years results of preclinical and clinical studies have suggested that LMWH may be able to inhibit cell growth, cell invasion, and angiogenesis, which are key mechanisms involved in tumor progression, possibly influencing favorable clinical outcome in at least a proportion of cancer patients.
  • In this work we investigated the effect of LMWH (enoxaparin) on cell growth and cell invasion in primary cell cultures obtained from high-grade glioma specimens: 5 anaplastic astrocytoma (AA) and 13 glioblastoma multiforme (GBM).
  • A significant decrease in tumor cell growth was observed after treatment with 10 U/ml (-21%; p = 0.001) and 100 U/ml (-26%; p < 0.001); tumor cells from AA (grade III;.
  • WHO) were more affected by LMWH treatment compared to cell lines from GBM (grade IV; WHO).
  • In conclusion, our results confirm the antineoplastic effect of LMWH, suggesting a potential direct role on tumor cell growth in high grade gliomas.
  • [MeSH-major] Brain Neoplasms / drug therapy. Cell Proliferation / drug effects. Enoxaparin / pharmacology. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Receptor, PAR-1 / biosynthesis. Receptor, PAR-1 / drug effects. Receptor, PAR-1 / genetics. Sensitivity and Specificity. Structure-Activity Relationship. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294805.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enoxaparin; 0 / Receptor, PAR-1
  •  go-up   go-down


61. Shibahara I, Kumabe T, Kanamori M, Saito R, Sonoda Y, Watanabe M, Iwata R, Higano S, Takanami K, Takai Y, Tominaga T: Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg; 2010 Aug;113(2):358-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Assessment of hypoxic conditions in brain tumors is important for predicting tumor aggressiveness and treatment response.
  • METHODS: The FRP-170 was injected and PET imaging was performed 2 hours later in 8 patients, including 3 with glioblastoma multiforme, 2 with oligodendroglioma, and 1 each with diffuse astrocytoma, anaplastic ganglioglioma, and recurrent anaplastic astrocytoma.
  • Tissues obtained at biopsy or radical resection were immunostained with hypoxia-inducible factor-1alpha (HIF-1alpha) antibody for the confirmation of hypoxia, except in the patient with recurrent anaplastic astrocytoma who was treated using Gamma Knife surgery.
  • RESULTS: The FRP-170 PET images showed marked uptake with upregulation of HIF-1alpha in the 3 glioblastomas multiforme, and moderate uptake in the recurrent anaplastic astrocytoma and one oligodendroglioma, but no uptake in the other tumors.
  • This new method can assess tumor hypoxia preoperatively and noninvasively.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Glioblastoma / radionuclide imaging. Hypoxia, Brain / radionuclide imaging. Nitroimidazoles. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Biopsy. Carbon Isotopes. Cell Division. Female. Fluorodeoxyglucose F18. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Methionine. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Protons. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895196.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / FRP-170; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nitroimidazoles; 0 / Protons; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


62. Nagpal J, Jamoona A, Gulati ND, Mohan A, Braun A, Murali R, Jhanwar-Uniyal M: Revisiting the role of p53 in primary and secondary glioblastomas. Anticancer Res; 2006 Nov-Dec;26(6C):4633-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) develops from astrocytes and is the most aggressive primary cancer in humans.
  • GBM may develop de novo (primary) or through progression from a low-grade or anaplastic astrocytoma (secondary).
  • Mutational inactivation of the p53 gene and presence of aberrant p53 expression are reported in GBM, suggesting that p53 has a role in tumor progression.
  • Our histopathological analysis showed that the expression of p53 in three out of four (75%) secondary GBM was confined to the nucleus and the p53 positive cells were randomly distributed throughout the tumor.
  • The expression of p53 in four out of seven (57%) de novo GBM was cytoplasmic, diffusive, and confined to the perivascular region of the tumor.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214319.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


63. Clark AJ, Dos Santos WG, McCready J, Chen MY, Van Meter TE, Ware JL, Wolber SB, Fillmore H, Broaddus WC: Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg; 2007 Sep;107(3):586-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status.
  • It has been demonstrated that Wilms tumor 1 (WT1) promotes tumor cell proliferation and survival in some cell lines by inhibiting p53-mediated apoptosis; however, this relationship has not been investigated in gliomas.
  • METHODS: The authors screened nine malignant glioma cell lines, 50 glioblastoma multiforme (GBM) samples, and 16 lower-grade glial tumors for WT1 expression.
  • RESULTS: Five of nine cell lines, 44 of 50 GBM samples, and 13 of 16 lower-grade gliomas expressed WT1 mRNA on reverse transcriptase polymerase chain reaction (PCR) analysis.
  • CONCLUSIONS: The presence of WT1 in glioma cell lines and the majority of primary tumor samples and its absence in normal astrocytes support the suggestion that WT1 expression is important in glioma biology.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Genes, p53 / genetics. Glioma / genetics. Glioma / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886559.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / WT1 Proteins
  •  go-up   go-down


64. Mangiola A, Lama G, Giannitelli C, De Bonis P, Anile C, Lauriola L, La Torre G, Sabatino G, Maira G, Jhanwar-Uniyal M, Sica G: Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res; 2007 Dec 1;13(23):6970-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications.
  • PURPOSE: It has been hypothesized that brain tumors are derived from stem cell or transiently dividing precursor transformation.
  • This study analyzes stem cell marker nestin and JNK expression in glioblastoma multiforme (GBM) and peritumor tissue and assesses their possible prognostic implications.
  • Samples were derived from tumors (first area), from tissues at a distance <1 cm (second area), and between 1 and 3.5 cm (third area) from the macroscopic tumor border.
  • RESULTS: Nestin cytoplasmic immunoreactivity was observed in the majority of cells in tumor but infrequently in peritumor areas. tJNK, observed in the nucleus and cytoplasm, was widely expressed in the three areas; pJNK, mostly located in the nuclei, was found in a variable percentage of cells in the tumor and peritumor tissue.
  • [MeSH-major] Glioblastoma / metabolism. Glioblastoma / pathology. Intermediate Filament Proteins / biosynthesis. JNK Mitogen-Activated Protein Kinases / biosynthesis. Nerve Tissue Proteins / biosynthesis. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Enzyme Activation. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Nestin. Prognosis. Stem Cells / metabolism. Stem Cells / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2008 Aug 1;14(15):4995-6
  • (PMID = 18056172.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


65. Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G: Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res; 2009 Oct 1;15(19):6258-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
  • PURPOSE: Phase I-II studies indicate that imatinib is active in glioblastoma multiforme.
  • To better understand the molecular and clinical effects of imatinib in glioblastoma multiforme, we conducted a neoadjuvant study of imatinib with pretreatment and posttreatment biopsies.
  • EXPERIMENTAL DESIGN: Patients underwent a computerized tomography-guided biopsy of their brain tumors.
  • If diagnosed with glioblastoma multiforme, they were immediately treated with 7 days of imatinib 400 mg orally twice daily followed by either definitive surgery or re-biopsy.
  • CONCLUSIONS: Intact imatinib was detected in glioblastoma multiforme tissue.
  • However, the histologic and immunoblotting evaluations suggest that glioblastoma multiforme proliferation and survival mechanisms are not substantially reduced by imatinib therapy in most patients.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / metabolism. Glioblastoma / drug therapy. Glioblastoma / metabolism. Piperazines / pharmacology. Piperazines / therapeutic use. Pyrimidines / pharmacology. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Benzamides. Biomarkers, Tumor / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Humans. Imatinib Mesylate. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoadjuvant Therapy. Oncogene Protein v-akt / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism. Signal Transduction / drug effects. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789313.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


66. Sminia P, Stoter TR, van der Valk P, Elkhuizen PH, Tadema TM, Kuipers GK, Vandertop WP, Lafleur MV, Slotman BJ: Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. J Cancer Res Clin Oncol; 2005 Oct;131(10):653-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.
  • PURPOSE: To investigate the pattern and level of cyclooxygenase-2 (COX-2) expression in a series of high grade primary and recurrent glioblastoma multiforme (GBM) and correlation with time to recurrence and patients' survival following therapy.
  • Tumor cell positivity was semi-quantitatively scored.
  • COX-2 scores of the primary tumor and recurrence were correlated with the time to radiological tumor progression and patients' survival.
  • RESULTS: COX-2 positive tumor cells were disseminated throughout the tumor parenchyma.
  • The intensity and pattern of COX-2 expression were heterogeneous, with predominant expression in areas surrounding tumor necrosis.
  • Primary GBMs with COX-2 expression levels between 25% and 70% of the tumor cells showed a shorter time to radiological recurrence than GBMs with <10% COX-2 positive tumor cells (respectively, 219 +/- 50 and 382 +/- 77 days).
  • No correlation was found between the COX-2 expression in the primary tumor and patients' survival (r (s) = -0.073) following therapy.
  • Hence, determination of COX-2 expression in tumor specimen for each individual might be relevant for selection of those patients, who could benefit from adjuvant therapy with selective COX-2 inhibitors.
  • [MeSH-major] Brain Neoplasms / metabolism. Cyclooxygenase 2 / biosynthesis. Glioblastoma / metabolism. Neoplasm Recurrence, Local / metabolism. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1002:236-43 [14751838.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 May;75(5):723-6 [15090567.001]
  • [Cites] Dig Dis Sci. 2003 Jan;48(1):197-202 [12645811.001]
  • [Cites] Semin Radiat Oncol. 2001 Oct;11(4):290-9 [11677654.001]
  • [Cites] Radiat Res. 2003 Dec;160(6):617-21 [14640786.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):886-94 [12377342.001]
  • [Cites] Neuropathology. 2004 Sep;24(3):201-7 [15484698.001]
  • [Cites] Annu Rev Med. 2002;53:35-57 [11818462.001]
  • [Cites] Cancer Control. 2004 May-Jun;11(3):152-64 [15153839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):895-8 [8598367.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40 [15565458.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):43-8 [15088099.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):657-62 [9012840.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001;51(3 Suppl 2):11-8 [11641010.001]
  • [Cites] Brain Res. 2002 Oct 4;951(2):218-26 [12270500.001]
  • [Cites] Front Radiat Ther Oncol. 1999;33:139-49 [10549484.001]
  • [Cites] Am J Surg. 2005 Jan;189(1):110-5 [15701502.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):369-75 [14751505.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1440-52 [14519750.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):263-8 [14719052.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):279-85 [14729635.001]
  • [Cites] Adv Exp Med Biol. 2002;507:107-12 [12664572.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7908-16 [10630643.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):872-7 [12576462.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):410-8 [11567815.001]
  • [Cites] Ann Diagn Pathol. 2002 Jun;6(3):148-53 [12089724.001]
  • [Cites] J Cell Mol Med. 2003 Jul-Sep;7(3):207-22 [14594546.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S272-5 [16507391.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4375-81 [11389063.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):318-27 [15890570.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):159-65 [9583731.001]
  • [Cites] Biochim Biophys Acta. 1999 Apr 19;1438(1):120-30 [10216286.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):632-5 [11830510.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1366-74 [14977838.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):329-38 [15558802.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):739-44 [16199309.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):927-31 [14967452.001]
  • (PMID = 16133570.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


67. Kashyap R, Ryan C, Sharma R, Maloo MK, Safadjou S, Graham M, Tretheway D, Jain A, Orloff M: Liver grafts from donors with central nervous system tumors: a single-center perspective. Liver Transpl; 2009 Oct;15(10):1204-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver grafts from donors with central nervous system tumors: a single-center perspective.
  • However, it has become a common practice to accept organs from donors that have low-grade tumors or tumors with low metastatic potential.
  • The aim of this study was to analyze our experience with the use of liver grafts from donors with central nervous system (CNS) tumors.
  • A retrospective review of 1173 liver transplants performed between 1992 and 2006 identified 42 donors diagnosed with a CNS tumor.
  • Twenty (47.6%) of the CNS tumors were glioblastoma multiforme (astrocytoma grade IV), 11 (26.2%) were other astrocytomas, and 1 (2.4%) was an anaplastic ependymoma.
  • Twenty (62.5%) neoplasms were grade IV tumors, 8 (25%) were grade II tumors, and 4 (12.5%) were grade III tumors.
  • Over 80% of the patients had at least 1 kind of invasive procedure violating the blood-brain barrier.
  • The rate of recurrence for the entire group was 2.4% (all CNS tumors).
  • There was no difference in survival between recipients of grafts from donors with CNS tumors and recipients of grafts from donors without CNS tumors (1 year: 82% versus 83.3%, P = not significant; 3 years: 77.4% versus 72%, P = not significant).
  • In conclusion, in our experience, despite violation of the blood-brain barrier and high-grade CNS tumors, recurrence was uncommon.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Liver Diseases / therapy. Liver Transplantation / methods. Tissue and Organ Procurement / methods
  • [MeSH-minor] Adult. Blood-Brain Barrier. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Time Factors. Tissue Donors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 AASLD
  • [CommentIn] Liver Transpl. 2010 Jul;16(7):916 [20583090.001]
  • [CommentIn] Liver Transpl. 2010 Jul;16(7):914-5 [20583288.001]
  • (PMID = 19790151.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Simonavicius N, Robertson D, Bax DA, Jones C, Huijbers IJ, Isacke CM: Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol; 2008 Mar;21(3):308-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma.
  • Gliomas are the most frequent primary tumors of the central nervous system in adults.
  • The most prevalent and aggressive subclass of these is glioblastoma multiforme, which is characterized by massive neovascularization.
  • We demonstrate here that endosialin is not expressed in normal human adult brain but is strongly upregulated in the angiogenic vasculature of all high-grade glioma specimens examined.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, Neoplasm / biosynthesis. Brain Neoplasms / blood supply. Glioblastoma / blood supply. Glioma / blood supply. Neovascularization, Pathologic / pathology. Pericytes / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal. Endothelial Cells / metabolism. Endothelial Cells / pathology. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192970.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD248 protein, human
  •  go-up   go-down


69. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL: Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer; 2008 Sep 1;113(5):1032-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme.
  • BACKGROUND: Regions of hypoxia within glioblastoma multiforme (GBM) are common and may influence a tumor's aggressiveness, response to treatment, and the patient's overall survival.
  • METHODS: In this retrospective cohort study, patients who had lower grade astrocytomas were compared with patients who had GBM to verify that the methods used could establish differences between tumor grades.
  • By using preoperative imaging, the amount of necrosis was established versus the overall tumor area.
  • The authors also compared preoperative images with postoperative images to define the amount of tumor resected; and they compared molecular markers, proliferation, MVD, and imaging studies with survival among patients who had GBM.
  • RESULTS: The hypoxia-regulated molecules (HRMs) and indices for MVD and cellular proliferation were associated significantly with tumor grade.
  • Survival was improved when >or=95% of the tumor was resected.
  • Although the total tumor area was associated with overall survival, no differences were observed when the amount of necrosis or a tumor necrosis index (area of necrosis/area of tumor) was compared with survival.
  • CONCLUSIONS: Tumor grade was differentiated with HRMs, MVD, and proliferation, but only GLUT-1 predicted survival in this group of patients with GBM.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [Cites] J Neurooncol. 1999;44(3):255-66 [10720205.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] J Neurosurg Sci. 2000 Dec;44(4):203-9; discussion 209-10 [11327289.001]
  • [Cites] Curr Opin Genet Dev. 2001 Jun;11(3):293-9 [11377966.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):29-35 [11395850.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1337-43 [11535709.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):57-66 [11849564.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):903-11 [12213585.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):537-52 [12687910.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):65-73 [8699228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9 [9223322.001]
  • [Cites] Croat Med J. 2005 Jun;46(3):417-22 [15861521.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):324-30 [15967109.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Neuropathology. 2005 Sep;25(3):201-6 [16193836.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74 [16286386.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):193-200 [16234986.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):162-70 [16721804.001]
  • [Cites] Brain Pathol. 2006 Oct;16(4):273-86 [17107596.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2441-8 [17438103.001]
  • [Cites] Cancer Treat Res. 2004;117:79-95 [15015553.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):971-80 [15313390.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2468-71 [8653677.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Stat Med. 1997 Nov 30;16(22):2529-42 [9403954.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):513-20 [9488306.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Oct;57(10):931-6 [9786243.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Expert Rev Mol Med. 2005 Apr 15;7(6):1-16 [15831177.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4621-31 [11030151.001]
  • (PMID = 18618497.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093247-06; United States / NCI NIH HHS / CA / T32 CA093247-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  • [Other-IDs] NLM/ NIHMS58348; NLM/ PMC2574798
  •  go-up   go-down


70. Liau CT, Wei KC, Tseng CK, Jung SM: Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. Chang Gung Med J; 2005 Jan;28(1):16-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
  • BACKGROUND: We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU.
  • Of these, 20 had glioblastoma multiforme and 22 had anaplastic astrocytoma.
  • The median time to tumor progression was 7.2 months (range, 0-88.7 months) and median survival time was 13.3 months (range, 1.7-88.7 months).
  • This combined modality treatment program was associated with reversible grade 3 to 4 hematological toxicity in 10 patients, with grade 3 ototoxicity in one patient and grade 2 neurotoxicity in one patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804144.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


71. Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T: Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol; 2006 Jun;58(3):394-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Common contrast-enhancing malignant tumors of the brain are glioblastoma multiforme (GBMs), anaplastic astrocytomas (AAs), metastases, and lymphomas, all of which have sometimes similar conventional MRI findings.
  • MATERIALS AND METHODS: Forty-eight patients with contrast-enhancing and histologically proven brain tumors, 14 AAs, 17 GBMs, nine metastases, and eight lymphomas, were included in the study.
  • Minimum ADC values (ADC(min)) of each tumor was later calculated from ADC map images.
  • PWI was applied using dynamic susceptibility contrast technique and maximum relative cerebral blood volume (rCBV(max)) was calculated from each tumor, given in ratio with contralateral normal white matter.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / diagnosis. Image Enhancement / methods. Lymphoma / diagnosis. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Volume / physiology. Cerebrovascular Circulation / physiology. Child. Contrast Media / administration & dosage. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527438.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


72. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH: Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest; 2008 Aug;88(8):808-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential.
  • Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells.
  • Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.
  • [MeSH-major] Antigens, CD / metabolism. Brain Neoplasms / immunology. Glioblastoma / immunology. Glycoproteins / metabolism. Neoplastic Stem Cells / immunology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Brain / pathology. Cells, Cultured. Drug Resistance, Neoplasm / immunology. Female. Gene Expression Profiling. Humans. Male. Mice. Mice, SCID. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18560366.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


73. Mills SJ, Soh C, Rose CJ, Cheung S, Zhao S, Parker GJ, Jackson A: Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging--derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol; 2010 Mar;31(3):549-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging--derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme.
  • BACKGROUND AND PURPOSE: ADC measurements have been shown to have an inverse relationship with tumor cell density.
  • Tumor VOIs were defined on the anatomic images and modified to contain only enhancing voxels.
  • This is important because it suggests that though the mechanisms underlying these parameters are theoretically similar, they actually reflect different aspects of tumor microenvironment.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Diffusion Tensor Imaging / methods. Glioblastoma / metabolism. Glioblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / metabolism. Cell Count. Contrast Media. Extracellular Space / metabolism. Female. Gadolinium DTPA. Humans. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850765.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C21247/A6840; United Kingdom / Cancer Research UK / / C21247/A7473
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


74. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


75. Price S, Harless W, Rikhye S, Altaha R: A fatal outcome in a patient with glioblastoma multiforme after receiving high-dose methotrexate. J Oncol Pharm Pract; 2008 Mar;14(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fatal outcome in a patient with glioblastoma multiforme after receiving high-dose methotrexate.
  • The most common adult primary brain tumor is glioblastoma multiforme (GBM).
  • Central nervous system tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Glioblastoma / drug therapy. Methotrexate / adverse effects
  • [MeSH-minor] Adult. Fatal Outcome. Female. Hernia / etiology. Humans. Intracranial Pressure / drug effects. Neurotoxicity Syndromes / etiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337442.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


76. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK: A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol; 2007 Feb;81(3):271-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
  • BACKGROUND: Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM).
  • There were 57 reports of toxicity of grade 3 or greater.
  • Non-fatal grade 3-4 granulocytopenia occurred in 15 patients (34%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. North America. Survival Analysis. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AAPS J. 2005 Mar 22;7(1):E14-9 [16146335.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2675-81 [11555579.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Drug Discov Today. 2005 Jan 15;10(2):107-14 [15718159.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 5):S31-5 [16085015.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2481-7 [12894531.001]
  • [Cites] Arch Neurol. 1981 Nov;38(11):696-9 [6975612.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):193-201 [14558594.001]
  • [Cites] Arch Surg. 1975 Aug;110(8):888-91 [1171673.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):189-95; discussion 196 [9457270.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Am J Med. 1983 Aug;75(2):289-94 [6881181.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] J Neurooncol. 1994;19(3):245-50 [7807175.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):43-6 [11550138.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] Immunopharmacology. 1996 Mar;31(2-3):213-21 [8861747.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):639-60; discussion 660-1 [12943581.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:d100-16 [12456339.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):635-44 [15497116.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1675-80 [8496685.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurooncol. 1994;18(3):207-16 [7964981.001]
  • (PMID = 17031561.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01CA62407
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


77. Seker A, Ozek MM: Congenital glioblastoma multiforme. Case report and review of the literature. J Neurosurg; 2006 Dec;105(6 Suppl):473-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital glioblastoma multiforme. Case report and review of the literature.
  • The definition of a "congenital" tumor is controversial.
  • The authors report the case of a "definite" congenital glioblastoma multiforme (GBM) diagnosed with the aid of ultrasonography and fetal magnetic resonance (MR) imaging in the 37th week of gestation.
  • Postnatal MR imaging revealed a massive tumor occupying the patient's left temporoparietooccipital area.
  • Surgery was performed, and the tumor was successfully excised completely.
  • The histopathological diagnosis of the tumor was GBM.
  • An examination of the tumor cells revealed no p53 accumulation, a high MIB-1 index (87.5%), and no staining for epidermal growth factor receptor (EGFR).
  • Congenital GBM should be considered in the differential diagnosis in cases in which a fetal ultrasonography study or fetal MR image reveals a tumor, especially in the presence of intratumoral hemorrhage.
  • Radical tumor removal, administration of adjuvant therapy, and biological findings (such as a lack of the overexpression of p53 and EGFR in the tumor cells) all point to a longer survival time.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / ultrasonography. Glioblastoma / surgery. Glioblastoma / ultrasonography
  • [MeSH-minor] Adult. Cerebral Angiography. Female. Fetal Diseases / ultrasonography. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Pregnancy. Ultrasonography, Prenatal


78. Fountzilas G, Karkavelas G, Kalogera-Fountzila A, Karina M, Ignatiadis M, Koukoulis G, Plataniotis G, Misailidou D, Bobos M, Pectasides D, Razis E, Karavelis A, Selviaridis P: Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res; 2006 Nov-Dec;26(6C):4675-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.
  • BACKGROUND: Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT).
  • PATIENTS AND METHODS: In the present study, a total of 45 HGAT patients, 38 with glioblastoma multiforme (GBM) and 7 with anaplastic astrocytoma (AA), were treated with TMZ, 150 mg/m(2) on days 1-5, followed by irinotecan, 150 mg/m(2) on days 6 and 17, every 4 weeks for 6 cycles or until the occurrence of unacceptable toxicity or disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / metabolism. Astrocytoma / therapy. Biomarkers, Tumor / biosynthesis. Brain Neoplasms / metabolism. Brain Neoplasms / therapy. Glioblastoma / metabolism. Glioblastoma / therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Combined Modality Therapy. Cyclooxygenase 2 / biosynthesis. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Feasibility Studies. Female. Humans. Ki-67 Antigen / biosynthesis. Male. Middle Aged. PTEN Phosphohydrolase / biosynthesis. Patient Compliance. Postoperative Care. Vascular Endothelial Growth Factor C / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214326.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor C; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


79. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF: MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol; 2005 Nov-Dec;26(10):2466-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging correlates of survival in patients with high-grade gliomas.
  • BACKGROUND AND PURPOSE: For patients with malignant gliomas, clinical data-including age, perioperative Karnofsky Performance Status (KPS), and tumor resection-and tumor imaging features-including necrosis and edema-have been found to correlate with survival.
  • METHODS: We analyzed the relationship between 15 imaging variables obtained from contrast-enhanced MR imaging scans and survival in patients with grade III (n = 43) and grade IV (n = 110) glioblastoma multiforme (GBM) gliomas.
  • RESULTS: As expected, age and KPS scores had significant prognostic value for both tumor grades.
  • For GBM, univariable analysis revealed the following imaging features to be significant, (hazard ratios in parentheses): noncontrast-enhancing tumor (nCET, 0.55), edema (1.62), satellites (1.74), and multifocality (4.34).
  • For grade III tumors, the Cox hazard ratio for necrosis was 4.43 (P = .014) and correlated with a poor outcome and survival rates comparable to GBM patients.
  • CONCLUSION: Of 15 tumor imaging features in GBM patients, only nCET, edema, and multifocality/satellites are statistically significant prognostic indicators.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Age Factors. Brain Edema / classification. Brain Edema / diagnosis. Female. Follow-Up Studies. Glioblastoma / classification. Glioblastoma / diagnosis. Glioblastoma / mortality. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm, Residual. Prognosis. Proportional Hazards Models. Reproducibility of Results. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286386.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Biassoni V, Casanova M, Spreafico F, Gandola L, Massimino M: A case of relapsing glioblastoma multiforme responding to vinorelbine. J Neurooncol; 2006 Nov;80(2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of relapsing glioblastoma multiforme responding to vinorelbine.
  • Vinorelbine is a semi-synthetic vinca alkaloid with an in vitro and in vivo experimentally proven broad spectrum of activity, including against malignant brain glioma.
  • We report our experience with a 19-year-old girl with glioblastoma multiforme (GBM) of the deep temporal region recurring 6 months after completing an intensive treatment that included preradiation chemotherapy (chemotherapy as a preradiation "sandwich" phase) with a myeloablative course of thiotepa, tumor bed radiotherapy and postradiation maintenance chemotherapy.
  • This case report suggests that vinorelbine is effective against high-grade pediatric glioma and, since this evidence has only one precedent in the literature (and given the generally poor prognosis for this tumor), even this single success seems worth reporting.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Temporal Lobe / pathology. Thiotepa / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1998;42(6):479-82 [9788574.001]
  • [Cites] Semin Oncol. 1989 Apr;16(2 Suppl 4):2-4 [2540531.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Neurosurg Focus. 2003 Feb 15;14(2):e1 [15727422.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1664-71 [15378498.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] J Neurosurg. 1981 Dec;55(6):917-21 [6271933.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3263-8 [12115359.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):201-9 [14970018.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):72-7 [10413158.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):41-8 [15701281.001]
  • (PMID = 16670944.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; 905Z5W3GKH / Thiotepa; Q6C979R91Y / vinorelbine
  •  go-up   go-down


81. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palù G: Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther; 2005 Oct;12(10):835-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results.
  • Following our pilot clinical study of combined IL-2/HSV-TK gene therapy for recurrent glioblastoma multiforme (GBM), we extended the protocol to a larger population of patients and evaluated safety, feasibility, and biological activity of treatment.
  • Transduction of tumor cells was demonstrated in tumor biopsies.
  • At magnetic resonance imaging evaluation, two patients had a partial response (including a patient showing disappearance of a distant noninjected tumor mass), four had a minor response, four had stable disease, and two had progressive disease.
  • In conclusion, the results of our clinical protocol of gene therapy for recurrent GBM, based on combined delivery of a suicide and a cytokine gene, demonstrate that intratumor injection of RVPCs was safe, provided effective transduction of the therapeutic genes to target tumor cells, and activated a systemic cytokine cascade, with tumor responses in 50% of cases.
  • [MeSH-major] Brain Neoplasms / therapy. Genes, Transgenic, Suicide / genetics. Genetic Therapy / methods. Glioblastoma / therapy. Interleukin-2 / therapeutic use. Simplexvirus. Thymidine Kinase / therapeutic use
  • [MeSH-minor] Adult. Aged. Cytokines / blood. Cytokines / metabolism. DNA Primers. Female. Genetic Vectors / genetics. Genetic Vectors / therapeutic use. Humans. Male. Middle Aged. Moloney murine leukemia virus. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891772.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA Primers; 0 / Interleukin-2; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


82. Moviglia GA, Carrizo AG, Varela G, Gaeta CA, Paes de Lima A, Farina P, Molina H: Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. Hematol Oncol Stem Cell Ther; 2008 Jan-Mar;1(1):3-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme.
  • BACKGROUND: Glioblastoma multiforme (GBM), the most aggressive glioma, presents with a rapid evolution and relapse within the first year, which is attributed to the persistence of tumor stem cells (TSC) and the escape of immune surveillance.
  • Tumor B-cell hybridoma (TBH) vaccines have been shown to function as antigen-presenting cells.
  • RESULTS: Treatment with MLC had strong and rapid therapeutic effects, but was limited in duration and induced various degrees of brain inflammation.
  • Treatment with MLC+TBH acted synergistically, provoking a rapid, strong and lasting therapeutic response but also generating different degrees of brain inflammation.
  • A lasting therapeutic effect without generating high degrees of brain inflammation occurred in patients treated with TBH vaccine alone.
  • CONCLUSION: TSC vaccine consisting of TBH alone seems to have potent adjuvant reactions overcoming both persistence of tumor stem cells and immune escape of GBM without provoking an encephalitic reaction.
  • [MeSH-major] B-Lymphocytes / transplantation. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Glioblastoma / therapy. Hybridomas / transplantation. Neoplastic Stem Cells / transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / transplantation. Lymphocyte Culture Test, Mixed. Male. Middle Aged. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063522.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


83. Gimenez M, Souza VC, Izumi C, Barbieri MR, Chammas R, Oba-Shinjo SM, Uno M, Marie SK, Rosa JC: Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin. Proteomics; 2010 Aug;10(15):2812-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin.
  • The aim of this study was to identify differentially expressed proteins in diffuse astrocytoma grade II, anaplastic astrocytoma grade III and glioblastoma multiforme grade IV in human tumor samples and in non-neoplastic brain tissue as control using 2-DE and MS.
  • Tumor and control brain tissue dissection was guided by histological hematoxylin/eosin tissue sections to provide more than 90% of tumor cells and astrocytes.
  • Six proteins were detected as up-regulated in higher grade astrocytomas and the most important finding was nucleophosmin (NPM) (p<0.05), whereas four proteins were down-regulated, among them raf kinase inhibitor protein (RKIP) (p<0.05).
  • We report here for the first time the alteration of NPM and RKIP expression in brain cancer.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Nuclear Proteins / genetics. Phosphatidylethanolamine Binding Protein / genetics. Proteomics
  • [MeSH-minor] Adult. Amino Acid Sequence. Brain / metabolism. Brain / pathology. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Proteins / genetics. Proteins / isolation & purification


84. Selkirk SM, Morrow J, Barone TA, Hoffer A, Lock J, DeChant A, Mangla S, Plunkett RJ, Miller RH: Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal. J Neurooncol; 2008 Feb;86(3):285-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal.
  • Osteopontin (OPN) is a pleotrophic molecule that has been associated with multiple disorders of the central nervous system (CNS).
  • Its roles in CNS malignancy are unclear but suggest that higher levels of OPN expression correlate with increased tumor grade and increased migratory capacity of tumor cells.
  • In this study OPN cDNA was cloned into a retroviral vector and used to infect F98 Fischer rat-derived glioma cells and U87 human-derived glioblastoma multiforme (GBM) cells in vitro.
  • Implantation of tumor cells expressing high levels of OPN into adult Fischer rats and nude rats resulted in morphologically distinct tumors and prolonged host survival relative to controls.
  • We propose that local produced, high level OPN expression limits the malignant character of glioma cells and that the downstream mechanisms involved represent pathways that may have therapeutic value in the treatment of human CNS malignancy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36328-34 [10593924.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10024-31 [17047065.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):342-51 [10896785.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24565-74 [10835423.001]
  • [Cites] Int J Exp Pathol. 2000 Dec;81(6):373-90 [11298186.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28261-7 [11375993.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1731-5 [11721059.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46024-30 [11590166.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] QJM. 2002 Jan;95(1):3-13 [11834767.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5336-43 [12235004.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6318-22 [12414663.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1198-205 [12606946.001]
  • [Cites] J Neuroimmunol. 2003 Mar;136(1-2):125-9 [12620651.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28593-606 [12771144.001]
  • [Cites] Mol Cancer Res. 2003 Sep;1(11):810-9 [14517343.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11051-64 [14704150.001]
  • [Cites] J Neuroimmunol. 2004 Oct;155(1-2):155-60 [15342207.001]
  • [Cites] Cell. 1979 Apr;16(4):885-93 [88265.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]
  • [Cites] J Biol Chem. 1987 Jul 15;262(20):9702-8 [3597437.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):426-30 [1729712.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Biochem J. 1994 Oct 1;303 ( Pt 1):255-62 [7945249.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):713-24 [7532190.001]
  • [Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):10110-6 [9092556.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):578-84 [9199622.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):219-26 [9892210.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:92-102 [9893260.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19381-92 [15757900.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6638-48 [16818637.001]
  • [Cites] Bioessays. 2006 Sep;28(9):923-34 [16937364.001]
  • [Cites] Ann N Y Acad Sci. 1999;890:204-22 [10668427.001]
  • (PMID = 17928956.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA10373602; United States / NINDS NIH HHS / NS / R01 NS036674; United States / NINDS NIH HHS / NS / NS030800-14; United States / NINDS NIH HHS / NS / R01 NS030800; United States / NINDS NIH HHS / NS / NS-3080011; United States / NINDS NIH HHS / NS / R37 NS036674; United States / NINDS NIH HHS / NS / R01 NS030800-14; United States / NINDS NIH HHS / NS / NS-36674-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 106441-73-0 / Osteopontin; 147336-22-9 / Green Fluorescent Proteins; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS196650; NLM/ PMC2911624
  •  go-up   go-down


85. Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Pollo B, Bissola L, Silvani A, Bianchessi D, D'Incerti L, Filippini G, Broggi G, Boiardi A, Finocchiaro G: Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res; 2007 May 1;13(9):2606-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Recent data suggest that methylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase (MGMT), by increasing the chemosensitivity of glioblastoma multiforme, is significantly associated with improved prognosis.
  • EXPERIMENTAL DESIGN: To address these issues, we have investigated the MGMT methylation status, clinical and magnetic resonance imaging characteristics, and relevant genetic features (loss of heterozygosity on 17p and 19q, EGFR amplification, and p53 mutations) in a retrospective study on 86 patients affected by glioblastoma multiforme: 72 patients had a clinical history indicating de novo insurgence of the tumor and the remaining 14 were secondary glioblastoma multiforme.
  • Mixed-nodular enhancement at magnetic resonance imaging was significantly more frequent in Meth+ and secondary glioblastoma multiforme and ring enhancement in Meth- and primary glioblastoma multiforme (P<0.005).
  • MGMT methylation was more present in secondary glioblastoma multiforme (P=0.006) and associated with loss of heterozygosity on 17p and/or 19q (P=0.005).
  • CONCLUSIONS: These observations suggest that MGMT methylation is part of a genetic signature of glioblastomas that developed from lower-grade gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Methylation. Glioblastoma / genetics. Loss of Heterozygosity. O(6)-Methylguanine-DNA Methyltransferase / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA, Neoplasm / metabolism. Female. Gene Amplification. Glioma / genetics. Glioma / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Receptor, Epidermal Growth Factor / genetics. Survival. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


86. Quan AL, Barnett GH, Lee SY, Vogelbaum MA, Toms SA, Staugaitis SM, Prayson RA, Peereboom DM, Stevens GH, Cohen BH, Suh JH: Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):695-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme.
  • PURPOSE: There have been conflicting reports in the literature regarding the prognostic significance of epidermal growth factor receptor (EGFR) amplification in patients with glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / genetics. Gene Amplification. Glioblastoma / genetics. Neoplasm Proteins / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Humans. Middle Aged. Prognosis. Radiotherapy Dosage. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936158.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


87. Sarissky M, Lavicka J, Kocanová S, Sulla I, Mirossay A, Miskovsky P, Gajdos M, Mojzis J, Mirossay L: Diazepam enhances hypericin-induced photocytotoxicity and apoptosis in human glioblastoma cells. Neoplasma; 2005;52(4):352-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diazepam enhances hypericin-induced photocytotoxicity and apoptosis in human glioblastoma cells.
  • Glioblastoma multiforme (GBM) is neoplasm which is resistant to all currently used treatment modalities including surgery, radiation therapy and chemotherapy.
  • For the study, we used U-87 MG and U373 MG glioma cell lines and primary cultures of GBM cells prepared from peroperatively obtained tumor specimens.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Brain Neoplasms / pathology. Diazepam / pharmacology. GABA Modulators / pharmacology. Glioblastoma / pathology. Perylene / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Drug Interactions. Female. Flow Cytometry. Humans. Male. Middle Aged. Photochemotherapy. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. PERYLENE .
  • Hazardous Substances Data Bank. DIAZEPAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16059654.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GABA Modulators; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; Q3JTX2Q7TU / Diazepam
  •  go-up   go-down


88. Ma JH, Kim HS, Rim NJ, Kim SH, Cho KG: Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions. AJNR Am J Neuroradiol; 2010 Oct;31(9):1699-706
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions.
  • BACKGROUND AND PURPOSE: The histogram method has been shown to demonstrate heterogeneous morphologic features of tumor vascularity.
  • This study aimed to determine whether whole-tumor histogram analysis of the normalized CBV for contrast-enhancing lesions and perienhancing lesions can differentiate among GBMs, SMTs, and lymphomas.
  • Histogram distribution of the normalized CBV was obtained from whole-tumor voxels in contrast-enhancing lesions and perienhancing lesions.
  • One-way ANOVA was used initially to test the overall equality of mean values for each type of tumor.
  • RESULTS: For whole-tumor histogram analyses for contrast-enhancing lesions, only PHP could differentiate among GBMs (4.79 ± 1.31), SMTs (3.32 ± 1.10), and lymphomas (2.08 ± 0.54).
  • CONCLUSIONS: Using a whole-tumor histogram analysis of normalized CBV for contrast-enhancing lesions and perienhancing lesions facilitates differentiation of GBMs, SMTs and lymphomas.
  • [MeSH-major] Blood Volume Determination / methods. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Glioblastoma / diagnosis. Glioblastoma / secondary. Lymphoma / diagnosis. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Lymphatic Metastasis. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581063.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Stelzer KJ, Douglas JG, Mankoff DA, Silbergeld DL, Krohn KA, Laramore GE, Spence AM: Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme. Neuro Oncol; 2008 Feb;10(1):88-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge.
  • Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning.
  • Median progression-free survival was 16 weeks, and all patients had tumor progression by 39 weeks.
  • Treatment was clinically well tolerated, but evidence of mild to moderate gliosis and microvascular sclerosis consistent with radiation injury was observed at autopsy in specimens taken from regions of contralateral brain that received approximately 6-10 Gy.
  • Fast neutron radiation using modern imaging, treatment planning, and beam delivery was feasible to a total dose of 18 Gy, but tumor control probability was poor in comparison to that predicted from a dose-response model based on older studies.
  • Steep dose-response curves for both tumor control and neurotoxicity continue to present a challenge to establishing a therapeutic window for fast neutron radiation in GBM, even with modern techniques.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1635-42 [11896114.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1667-73 [12468518.001]
  • [Cites] J Neurosurg. 1978 Jul;49(1):1-12 [207833.001]
  • [Cites] Cancer. 1978 Jul;42(1):96-103 [96933.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Mar;6(3):261-6 [6248495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):679-86 [2984151.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1093-102 [2838442.001]
  • [Cites] Med Dosim. 1991 Sep;16(3):137-41 [1910470.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] J Neurooncol. 1997 May;33(1-2):171-8 [9151234.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95 [9457811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):886-91 [16242251.001]
  • (PMID = 18055860.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA042045; United States / NCI NIH HHS / CA / P01 CA 42045
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 40871-47-4 / 2-fluoro-2-deoxyglucose-6-phosphate; 56-73-5 / Glucose-6-Phosphate
  • [Other-IDs] NLM/ PMC2600842
  •  go-up   go-down


90. Di Ieva A, Grizzi F, Tschabitscher M, Colombo P, Casali M, Simonelli M, Widhalm G, Muzzio PC, Matula C, Chiti A, Rodriguez y Baena R: Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings. Microvasc Res; 2010 Sep;80(2):267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings.
  • Neuroradiological and metabolic imaging is a fundamental diagnostic procedure in the assessment of patients with primary and metastatic brain tumors.
  • The correlation between objective parameters capable of quantifying the neoplastic angioarchitecture and imaging data may improve our understanding of the underlying physiopathology and make it possible to evaluate treatment efficacy in brain tumors.
  • Only a few studies have so far correlated the quantitative parameters measuring the neovascularity of brain tumors with the metabolic profiles measured by means of amino acid uptake in positron emission tomography (PET) scans.
  • In this study, we evaluated the microvascular network complexity of six cases of human glioblastoma multiforme quantifying the surface fractal dimension on CD34 immunostained specimens.
  • The different fractal dimension values observed showed that the same histological category of brain tumor had different microvascular network architectures.
  • Our preliminary findings indicate that that vascularity (estimated on the histologic specimens by means of the fractal dimension) and (11)C-methionine uptake (assessed by PET) closely correlate in glioblastoma multiforme and that microvascular fractal dimension can be a useful parameter to objectively describe and quantify the geometrical complexity of the microangioarchitecture in glioblastoma multiforme.
  • [MeSH-major] Carbon Radioisotopes / pharmacokinetics. Glioblastoma / pathology. Methionine / pharmacokinetics. Microvessels / pathology. Neovascularization, Pathologic / pathology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Biological Transport. Female. Fractals. Humans. Image Processing, Computer-Assisted. Male. Middle Aged